Page last updated: 2024-11-04

mebendazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mebendazole is a benzimidazole derivative that acts as an anthelmintic drug, primarily used to treat intestinal infections caused by roundworms such as Ascaris lumbricoides, Trichuris trichiura, and hookworms. It works by interfering with the uptake of glucose by the parasite, leading to its death. Mebendazole is typically administered orally and is readily absorbed in the gastrointestinal tract. It is effective against a wide range of parasitic nematodes and is considered safe for long-term use. However, mebendazole is not recommended for pregnant women or breastfeeding mothers. The synthesis of mebendazole involves several steps, including the reaction of 2-aminophenol with benzoyl chloride, followed by cyclization and methylation. Mebendazole is a widely studied compound due to its effectiveness in treating parasitic infections, especially in developing countries where these infections are prevalent. Research focuses on understanding its mechanism of action, optimizing its efficacy, and exploring its potential for other medical applications.'

Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4030
CHEMBL ID685
CHEBI ID6704
SCHEMBL ID15860
MeSH IDM0013158

Synonyms (227)

Synonym
BIDD:GT0087
methyl n-(6-benzoyl-1h-1,3-benzodiazol-2-yl)carbamate
AB00052203-09
BRD-K77987382-001-01-7
BRD-K77987382-001-06-6
mebenvet
nsc184849
vermirax
r 17,635
telmin
methyl 5-benzoyl-2-benzimidazolylcarbamate
mebenoazole
mebutar
pantelmin
vermox
31431-39-7
nsc-184849
ovitelmin
r 17635
methyl 5-benzoyl-2-benzimidazolecarbamate
mebendazole
5-benzoyl-2-benzimidazolecarbamic acid, methyl ester
KBIO1_000751
DIVK1C_000751
sufil
n-(benzoyl-5, benzimidazolyl)-2, carbamate de methyle [french]
einecs 250-635-4
carbamic acid, n-(5-benzoylbenzimidazol-2-yl)-, methyl ester
mebendazolum [inn-latin]
methyl n-(5-benzoyl-2-benzimidazolyl)carbamate
hsdb 3232
2-benzimidazolecarbamic acid, 5-benzoyl-, methyl ester
mebendazol [inn-spanish]
n-2 (5-benzoyl-benzimidazole) carbamate de methyle [french]
noverme
methyl 5-benzoyl benzimidazole-2-carbamate
nsc 184849
versid
SPECTRUM_001298
TIMTEC1_000869
c16h13n3o3
PRESTWICK_310
cas-31431-39-7
NCGC00016806-01
CBDIVE_010559
OPREA1_768530
BSPBIO_003178
SPECTRUM5_001381
(5-benzoyl-1h-benzimidazol-2-yl)carbamic acid methyl ester
methyl n-(5-benzoyl-1h-benzimidazol-2-yl)carbamate
OPREA1_278237
BPBIO1_000257
PRESTWICK2_000217
PRESTWICK3_000217
PROBES1_000013
STK093862
carbamic acid, (5-benzoyl-1h-benzimidazol-2-yl)-, methyl ester
bantenol
2-benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8ci)
ccris 4479
lomper
carbamic acid, (5-benzoyl-1h-benzimidazol-2-yl)-, methyl ester (9ci)
besantin
mbdz
mebex
vermicidin
5-benzoyl-2-benzimidazolecarbamic acid methyl ester
verpanyl
equivurm plus
AB00052203
DB00643
D00368
vermox (tn)
mebendazole (jan/usp/inn)
PROBES2_000149
BSPBIO_000233
(5-benzoyl-1h-benzimidazol-2-yl)-carbamic acid methyl ester
CHEBI:6704 ,
methyl (5-benzoyl-1h-benzimidazol-2-yl)carbamate
NCGC00021698-04
NCGC00021698-03
smr000036734
MLS000028491
KBIO2_004346
KBIOGR_000712
KBIO2_001778
KBIOSS_001778
KBIO3_002398
KBIO2_006914
PRESTWICK1_000217
SPECTRUM3_001439
PRESTWICK0_000217
SPBIO_002154
NINDS_000751
SPBIO_001442
SPECTRUM4_000416
SPECTRUM2_001401
SPECTRUM1501110
IDI1_000751
NCGC00016806-02
NCGC00021698-06
NCGC00021698-05
methyl [5-(phenylcarbonyl)-1h-benzimidazol-2-yl]carbamate
HMS1536H11
HMS2090B03
AC-12064
HMS2092B15
zhihuanqing
r-17635
mebendazolum
CHEMBL685 ,
HMS502F13
bdbm50180753
AKOS000539066
HMS1568L15
HMS1921F03
methyl n-(6-benzoyl-1h-benzimidazol-2-yl)carbamate
cpd000036734
NCGC00021698-07
HMS3259B11
HMS2095L15
M2273
methyl [5-(benzoyl)benzimidazol-2-yl]carbamate
EN300-50844
BBL008298
A820852
5-benzoyl-1h-benzimidazol-2-yl carbamic acid methyl ester;
nsc-757838
pharmakon1600-01501110
nsc757838
dtxcid2020682
dtxsid4040682 ,
tox21_110620
S4610
CCG-39628
NCGC00016806-04
NCGC00016806-05
NCGC00016806-10
NCGC00016806-06
NCGC00016806-09
NCGC00016806-07
NCGC00016806-03
NCGC00016806-08
mebendazol
mebendazole [usan:usp:inn:ban:jan]
81g6i5v05i ,
n-(benzoyl-5, benzimidazolyl)-2, carbamate de methyle
emverm
n-2 (5-benzoyl-benzimidazole) carbamate de methyle
unii-81g6i5v05i
FT-0628180
FT-0628179
NCGC00016806-12
mebendazole [usp impurity]
mebendazolum [who-ip]
mebendazole [mart.]
mebendazole [usan]
mebendazole [orange book]
mebendazole [usp-rs]
mebendazole [jan]
mebendazole [inn]
mebendazole [green book]
mebendazole [usp monograph]
mebendazole [vandf]
mebendazole [hsdb]
mebendazole [ep monograph]
mebendazole [who-dd]
mebendazole [who-ip]
AKOS015896232
methyl (5-benzoyl-1h-benzo[d]imidazol-2-yl)carbamate
NC00639
SCHEMBL15860
tox21_110620_1
NCGC00016806-13
CS-3974
cambridge id 5250893
AG-205/04588045
MLS006011879
methyl (6-benzoyl-1h-benzimidazol-2-yl)carbamate
W-106901
HY-17595
OPXLLQIJSORQAM-UHFFFAOYSA-N
methyl 6-benzoyl-1h-benzimidazol-2-ylcarbamate
mebatreat
equivurmp plus
HMS3604N11
AB00052203_10
mfcd00057872
Z234895185
sr-01000003109
SR-01000003109-2
mebendazole, united states pharmacopeia (usp) reference standard
mebendazole, vetranal(tm), analytical standard
mebendazole for system suitability, european pharmacopoeia (ep) reference standard
mebendazole, analytical standard, >=98% (hplc)
mebendazole, european pharmacopoeia (ep) reference standard
SR-01000003109-3
SBI-0051641.P002
HMS3712L15
mmv003152
Q422194
5-benzoyl-2-benzimidazolylcarbamicacidmethylester
V95 ,
mebendazole,(s)
methyl 5-benzoyl-1h-benzo[d]imidazol-2-ylcarbamate
AS-12272
BRD-K77987382-001-08-2
D70118
SY051142
methyl n-[6-(benzoyl)-1h-benzimidazol-2-yl]carbamate
SR-01000003109-10
mebendazole; 4030
mebendazole for system suitability
telmintic powder
mebendazol (inn-spanish)
telmin equine wormer
telmin syringe formula
mebendazole (ep monograph)
mebendazole (usp impurity)
mebendazole (usp-rs)
mebendazole (mart.)
equivrm plus
mebendazolum (inn-latin)
p02ca01
mebendazole (usan:usp:inn:ban:jan)
mebendazolo
mebendazole (usp monograph)

Research Excerpts

Overview

Mebendazole (MBZ) is an efficacious anthelmintic with known anti-inflammatory and fibrinolytic properties. It is a broad-spectrum antihelminthic agent of the benzimidazole type. Meb endazole is an extremely insoluble and therefore poorly absorbed drug.

ExcerptReferenceRelevance
"Mebendazole (MBZ) is a well-known anti-parasite drug with significant anti-cancer properties. "( Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment.
Ghahremani, F; Hosseini, M; Jolfaie, NA; Kefayat, A; Rafienia, M, 2022
)
2.39
"Mebendazole (MBZ) is a synthetic benzimidazole known for its antiparasitic properties. "( Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death.
Cui, Y; Huang, M; Li, H; Sha, J; Wang, C; Yao, Y; Yuan, Y; Zhu, Y, 2022
)
3.61
"Mebendazole (MBZ) is an efficacious anthelmintic with known anti-inflammatory and fibrinolytic properties. "( Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis.
Ahadi, M; Asgharzadeh, F; Askarnia-Faal, MM; Avan, A; Eskandari, M; Ferns, G; Gharib, M; Hassanian, SM; Khazaei, M; Naghibzadeh, N; Naimi, H; Ryzhikov, M; Soleimani, A; Vossoughinia, H, 2022
)
3.61
"Mebendazole (MBZ) is a broad-spectrum antihelminthic agent of the benzimidazole type. "( Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome.
Cascio, A; Colomba, C; Meli, M; Tolomeo, M, 2019
)
2.26
"Mebendazole (MBZ) is a tubulin-suppressive antihelmintic agent with low toxicity, which has been repurposed to treat different types of tumors. "( Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells.
Lou, K; Ma, H; Song, X; Wang, W; Wang, X; Xu, H; Zhou, X, 2020
)
3.44
"Mebendazole is an effective drug for the treatment."( Gallbladder ascariasis in Kosovo - focus on ultrasound and conservative therapy: a case series.
Avdiu, M; Azemi, M; Hoxha-Kamberi, T; Ismaili-Jaha, V; Jaha, L; Spahiu, L; Spahiu-Konjusha, S; Toro, H, 2018
)
1.2
"Mebendazole is an antihelminthic drug that exerts its effects via interference with microtubule function in parasites. "( Mebendazole reduces vascular smooth muscle cell proliferation and neointimal formation following vascular injury in mice.
Eitzman, DT; Guo, C; Lawler, A; Luo, W; Reddy, A; Sun, EB; Wang, H; Wang, J, 2014
)
3.29
"Mebendazole (MBZ) is an extremely insoluble and therefore poorly absorbed drug and the variable clinical results may correlate with blood concentrations. "( Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose.
Bolás-Fernández, F; de la Torre-Iglesias, PM; García-Rodriguez, JJ; Torrado, G; Torrado, S; Torrado-Santiago, S, 2014
)
2.09
"Mebendazole (MBZ) is an anthelmintic drug which inhibits tubulin polymerization and eventually causes apoptosis in target organisms. "( EFFECT OF THE ANTIPARASITIC DRUG MEBENDAZOLE ON CHOLANGIOCARCINOMA GROWTH.
Riggins, GJ; Sawanyawisuth, K; Williamson, T; Wongkham, S, 2014
)
2.13
"Mebendazole (MEB) is a widely used broad spectrum anthelmintic drug of the benzimidazole class, which exhibits structural polymorphism (Forms A-C)."( Mebendazole crystal forms in tablet formulations. An ATR-FTIR/chemometrics approach to polymorph assignment.
Calvo, NL; Kaufman, TS; Maggio, RM, 2016
)
2.6
"Mebendazole is an effective drug widely used in the treatment of parasitic infections. "( Safety of Mebendazole Use During Lactation: A Case Series Report.
Berkovitch, M; Berlin, M; Cohen, R; Dinavitser, N; Karra, N; Koren, G, 2016
)
2.28
"Mebendazole (MBZ) is a common benzimidazole anthelmintic that exists in three different polymorphic forms, A, B, and C. "( Intermolecular contacts influencing the conformational and geometric features of the pharmaceutically preferred mebendazole polymorph C.
Brusau, EV; Camí, GE; Ellena, J; Martins, FT; Narda, GE; Neves, PP, 2009
)
2.01
"Mebendazole is an anthelmintic that is commonly needed in women of reproductive age. "( Pregnancy outcome after gestational exposure to mebendazole: a prospective controlled cohort study.
Arnon, J; Diav-Citrin, O; Lubart, I; Ornoy, A; Shechtman, S, 2003
)
2.02
"Mebendazole is a benzimidazole anthelmintic widely used in veterinary and human therapy. "( The effects of mebendazole on P4501A activity in rat hepatocytes and HepG2 cells. Comparison with tiabendazole and omeprazole.
Baliharová, V; Bull, S; De Vrieze, G; Fink-Gremmels, J; Maas, RF; Skálová, L, 2003
)
2.11
"Mebendazole is a common benzimidazole anthelmintic that is water insoluble. "( Variable-temperature X-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole.
de Villiers, MM; Dekker, TG; Liebenberg, W; Song, M; Swanepoel, E; Terblanche, RJ, 2005
)
1.97
"Mebendazole is an anthelmintic drug widely used in Cuba and in Mexico. "( Genotoxic activity of mebendazole in Aspergillus nidulans.
Cortinas de Nava, C; de la Torre, RA; Espinosa-Aguirre, JJ; Izquierdo, T; Moron, F, 1994
)
2.05
"Mebendazole is an effective treatment."( Tackling threadworms.
Harcup, J, 1995
)
1.01
"Mebendazole is an effective medication for this disease, but the long term effect of praziquantel is not certain."( [Armillifer agkistrodontis disease: report of case].
Huang, M; Wang, B; Zhang, Q, 1996
)
1.02
"Mebendazole appears to be a safe drug for use in the treatment of human parasitic intestinal nematode infestations, and should be especially useful in the treatment and control of trichuriasis."( Evaluation of a new antihelminthic for trichuriasis, hookworm, and stronglyloidiasis.
Hawes, RB; Jameson, JL; Musgrave, IA; Quayle, PA; Sloane, RA, 1979
)
0.98
"Mebendazole appears to be a safe drug for use in the treatment of human parasitic intestinal nematode infestations and should be especially useful in the treatment and control of trichuriasis."( Evaluation of a new antihelminthic for trichuriasis, hookworm, and stronglyloidiasis.
Hawes, RB; Jameson, JL; Musgrave, IA; Quayle, PA; Sloane, RA, 1979
)
0.88

Effects

Mebendazole has been approved by the US Food and Drug Administration for parasitic infections. The drug has a long track-record of safe human use, and was effective in our animal models.

ExcerptReferenceRelevance
"Mebendazole (MBZ) has a long safety record as antiparasitic in children and has been recently implicated in inhibition of various tyrosine kinases in vitro."( Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.
Bai, RY; Bunz, F; Riggins, GJ; Rudin, CM; Staedtke, V, 2015
)
1.38
"Mebendazole has been shown to inhibit microtubule formation, but it is not known whether its potency against tumor cells is mediated by this inhibitory effect."( Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.
Al Dimassi, S; Atlas, M; Boockvar, J; De Witt, M; Gamble, A; Hanson, D; Markowitz, D; Powell, C; Ruggieri, R; Symons, M, 2017
)
1.56
"Mebendazole (MBZ) has a long safety record as antiparasitic in children and has been recently implicated in inhibition of various tyrosine kinases in vitro."( Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.
Bai, RY; Bunz, F; Riggins, GJ; Rudin, CM; Staedtke, V, 2015
)
1.38
"Mebendazole (MBZ) has been licensed for use in horses and donkeys, however there are no data available in the literature regarding its pharmacokinetic disposition and efficacy in donkeys. "( Plasma disposition, milk excretion and parasitological efficacy of mebendazole in donkeys naturally infected by Cyathostominae.
Aksit, D; Buono, F; Fagiolo, A; Gokbulut, C; Mariani, U; Roncoroni, C; Rufrano, D; Santoro, M; Veneziano, V, 2016
)
2.11
"Mebendazole (MBZ), has been used as antitubulin drug."( Silicon nanowire based biosensing platform for electrochemical sensing of Mebendazole drug activity on breast cancer cells.
Abdolahad, M; Alikhani, A; Faramarzpour, M; Hassanpour, M; Namdar, N; Shashaani, H, 2016
)
1.39
"Mebendazole has been approved by the US Food and Drug Administration for parasitic infections, has a long track-record of safe human use, and was effective in our animal models with doses documented as safe in humans."( Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.
Aprhys, CM; Bai, RY; Gallia, GL; Riggins, GJ; Staedtke, V, 2011
)
1.45
"Mebendazole has proved effective in the treatment of secondary echinococcosis."( [Treatment of peritoneal hydatidosis with mebendazole. Preliminary study (author's transl)].
Alba, J; Esteban, JA; García Mérida, M; Iglesia, P, 1981
)
1.25
"Mebendazole has been found to be ovicidal for the eggs of roundworm, hookworm, and whipworm with the disadvantages of cost and long duration of therapy; it is also considered the best drug for the treatment of trichuriasis."( Mebendazole.
Keystone, JS; Murdoch, JK, 1979
)
2.32
"Mebendazole has been used as the pharmacological standard reference."( An experimental in vitro model for evaluating drugs against protoscoleces of Echinococcus granulosus.
Lorenzini, R; Ruggieri, A, 1990
)
1
"Mebendazole has no effect on hexokinase which has broad substrate specificity but influences the activities of some glycolytic enzymes such as phosphorylase, phosphoglucomutase and glucose-6-phosphatase."( In vitro effects of mebendazole on the carbohydrate metabolism of Avitellina lahorea (Cestoda).
Ahmad, M; Nizami, WA, 1987
)
1.32
"Why mebendazole, which has been previously reported to both suppress embryogenesis and lower skin mf counts, had no effect in this study is unknown."( Fluorescein angiographic studies of mebendazole treatment for onchocerciasis.
Awadzi, K; George, T; Murphy, RP; Schulz-Key, H; Taylor, HR, 1985
)
1.03

Actions

ExcerptReferenceRelevance
"Mebendazole displays polymorphism. "( [Infrared spectrometry determination of polymorphic form C in mebendazole].
Gao, H; Sha, ZF; Sun, WJ, 1989
)
1.96

Treatment

Mebendazole treatment was associated with a median percentage reduction in ova count of 72.2%, which significantly exceeded the 44.1% reduction after albendazol. Treatment resulted in an increase in the concentration of alanine, valine, lysine, and taurine in both cyst wall and cyst fluid.

ExcerptReferenceRelevance
"Mebendazole treatment did not reduce the risk of anaemia."( Trichuris and hookworm infections associated with anaemia during pregnancy.
Casapía, M; Gilbert, NL; Gyorkos, TW; Larocque, R, 2011
)
1.09
"Mebendazole treatment was begun."( [Hepatocellular carcinoma complicated with echinococcal cyst of the liver].
Dragnev, N; Kobakov, G; Kostov, D; Patanov, R, 2010
)
1.08
"Mebendazole treatment complemented with health education."( Soil transmitted nematodes in children in Buea Health District of Cameroon.
Matute, MM; Ndamukong, KJ; Ndenecho, L, 2002
)
1.76
"Mebendazole treatment significantly reduced the intensities of infection with Ascaris and Trichuris (P<0.05)."( Soil transmitted nematodes in children in Buea Health District of Cameroon.
Matute, MM; Ndamukong, KJ; Ndenecho, L, 2002
)
1.04
"Mebendazole treatment caused unexpected and significant reductions in wasting malnutrition and anemia in very young children with light infections."( Low dose daily iron supplementation improves iron status and appetite but not anemia, whereas quarterly anthelminthic treatment improves growth, appetite and anemia in Zanzibari preschool children.
Albonico, M; Chway, HM; Jape, JK; Montresor, A; Savioli, L; Stoltzfus, RJ; Tielsch, JM, 2004
)
1.04
"Mebendazole-treated subjects remained worm-free and the hookworm egg counts of the controls decreased during the study period."( The relationship of hookworm infection, anaemia and iron status in a Papua New Guinea highland population and the response to treatment with iron and mebendazole.
Blunden, RW; Casey, GJ; Kimber, RJ; Kutkaite, D; Payne, R; Shield, JM; Vaterlaws, AL, 1981
)
1.18
"Mebendazole treatment resulted in an increase in the concentration of alanine, valine, lysine, and taurine in both cyst wall and cyst fluid, the most notable being the alanine in the cyst wall."( Effect of mebendazole on free amino acid composition of cyst wall and cyst fluid of Echinococcus granulosus harbored in mice.
Feng, JJ; Shimada, M; Xiao, SH; Xue, CL; Yao, MY, 1994
)
1.41
"Mebendazole treatment was associated with a median percentage reduction in ova count of 72.2%, which significantly exceeded the 44.1% reduction after albendazole (P = 0.024)."( A comparison of mebendazole and albendazole in treating children with Trichuris trichiura infection in Durban, South Africa.
Cheetham, RF; Epstein, SR; Gouws, E; Jackson, TF, 1998
)
1.37
"Mebendazole-treated mice had a significant decrease in the total number of cysts (15 vs."( Chemotherapy of hydatid disease (Echinococcus granulosus) in mice with mebendazole and bithionol.
Judge, DM; Kammerer, WS, 1976
)
1.21
"Mebendazole treatment was well tolerated by all patients."( [Long-term therapy of cystic liver echinococcosis with mebendazole].
Dietrich, M; Kern, P; Rippmann, K, 1992
)
1.25
"Mebendazole (MBZ) treatment at the early prepatent (5-7 weeks of post infection) or the late prepatent (7-9 weeks of post infection) period was highly effective in causing almost complete eradication of the primary infection."( Induction of protective immunity to Brugia pahangi in jirds by drug-abbreviated infection.
Fujita, K; Horii, Y; Kurokawa, K; Mori, A; Nakanishi, H; Oda, T; Ueda, M; Zaitsu, M, 1992
)
1
"Mebendazole treatment induced a decrease of glucose (81%) whereas Isoprinosine increased the glucose uptake in the parasite."( Treatment of experimental alveolar echinococcosis: comparative study of mebendazole, isoprinosine and a mebendazole isoprinosine association.
al-Nahhas, S; Petavy, AF; Raynaud, G; Sarciron, ME; Walbaum, S, 1991
)
1.23
"Mebendazole treatment was not considered to be an alternative to surgical treatment and was only used in specific cases."( [Hydatid cysts in children].
Ertaskin, I; Keskin, E; Okur, H; Olcay, I; Zorludemir, U, 1991
)
1
"Oral treatment with mebendazole 20mg/kg (Telmin(®)) was effective in curing the infection."( Resolution of canine ocular thelaziosis in avermectin-sensitive Border Collies from Spain.
Alarcón-Elbal, PM; Calero-Bernal, R; Dantas-Torres, F; Latrofa, MS; Otranto, D; Sánchez-Moro, J; Sánchez-Murillo, JM, 2014
)
0.72
"Treatment with mebendazole resulted in a rapid resolution of symptoms and disappearance of the eosinophilia, which strongly suggested a causative role of this pinworm in the clinical syndrome of the patient."( [Severe diarrhea and eosinophilic colitis attributed to pinworms (Enterobius vermicularis)].
Baan, J; de Jong, MD; Lommerse, E; van Gool, T, 2003
)
0.66
"Treatment with mebendazole in combination with IL-12, however, resulted in low levels of worm recovery and dramatic lessening of the eosinophilic meningitis."( Combined treatment with interleukin-12 and mebendazole lessens the severity of experimental eosinophilic meningitis caused by Angiostrongylus cantonensis in ICR mice.
Du, WY; Fan, CK; Liao, JW; Su, KE, 2003
)
0.92
"Treatment with mebendazole and steroids was effective."( Eosinophilic meningitis in a returned traveler from Santo Domingo: case report and review.
De Marco, M; Esposito, M; Ghirga, P; Leone, S; Narciso, P; Nicastri, E,
)
0.47
"Treatment with mebendazole was ineffective; the patient's tolerance for the newer drug praziquantel was extremely poor."( Human proliferative sparganosis in Venezuela: report of a case.
de NOya, BA; Martinez, E; Moulinier, R; Noya, O; Reyes, O; Torres, J, 1982
)
0.6
"Treatment with mebendazole and thiabendazole was efficacious against all the intestinal nematodes, with the exception of mebendazole versus Streptopharagus sp."( A survey for intestinal helminths in recently wild-caught Macaca mulatta and results of treatment with mebendazole and thiabendazole.
Else, JG; Henrickson, RV; Karr, SL, 1980
)
0.82
"Treatment with mebendazole is indicated for the entire family."( Common intestinal helminths.
Juckett, G, 1995
)
0.63
"Treatment (mebendazole) or placebo tablets were administered every 2 mo for 8 mo and again at 12 mo."( Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status.
Lunn, PG; Mascie-Taylor, CN; Northrop-Clewes, CA; Rousham, EK, 2001
)
0.68
"Treatment with mebendazole reduced the prevalence of Ascaris lumbricoides from 78% to 8%, of Trichuris trichiura from 65% to 9%, and of hookworm from 4% to 0%. "( Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, growth, and biochemical status.
Lunn, PG; Mascie-Taylor, CN; Northrop-Clewes, CA; Rousham, EK, 2001
)
0.66
"Treatment with mebendazole was successful."( Cutaneous larva migrans--a traveller's disease.
Allen, CP, 1990
)
0.62
"Treatment with mebendazole (1.5 g per day) for 21 days led to the disappearance of the clinical symptoms and microfilariae, and to a decrease of eosinophilia to normal values."( Treatment of recurrent, filarial, Calabar-type oedema with mebendazole.
Flocard, F; Van Hoegaerden, M, 1986
)
0.85
"The treatment with mebendazole of larval E."( [Experimental therapy in Chinese hamsters and rats infected with larval Echinococcus multilocularis by using mebendazole, albendazole and ivermectin with brief review of chemotherapy of human multilocular echinococcosis].
Inaoka, T; Kutsumi, H; Nakao, M; Ohnishi, K, 1987
)
0.8

Toxicity

A trial was devised to assess whether the administration of selenium and cobalt together with the anthelmintic mebendazole (Ovitelmin S&C) was safe. Mixed breed dogs that received increasing doses of meb endazole at 11 to 110 times the therapeutic dose for 2 months did not show adverse effects.

ExcerptReferenceRelevance
"A trial was devised to assess whether the administration of selenium and cobalt together with the anthelmintic mebendazole (Ovitelmin S&C) was safe and could improve the supplies of selenium and cobalt for adult sheep fed a whole grain diet, low in both elements, which produced a steady decrease in blood glutathione peroxidase (GSHPx) and plasma vitamin B12 concentrations."( An assessment of the efficacy and safety of selenium and cobalt included in an anthelmintic for sheep.
Brebner, J; Field, AC; Gunn, GW; Suttle, NF, 1988
)
0.49
" Adverse effects were generally limited to slight softening of the feces."( Critical test and safety evaluations of an oral paste preparation of mebendazole and trichlorfon in horses.
Michael, BF; Newcomb, KM; Seibert, BP, 1986
)
0.51
"In an attempt to test the biological activity of three polymorphic forms of mebendazole (MBZ), called A, B and C, both the LD50 in mice after oral (p."( Experimental chemotherapy and toxicity in mice of three mebendazole polymorphic forms.
Criado-Fornelio, A; Guzman, L; Igual, A; Jimenez-Gonzalez, A; Perez, A; Pujol, M; Rodriguez-Caabeiro, F, 1987
)
0.75
" Mixed breed dogs that received increasing doses of mebendazole at 11 to 110 times the therapeutic dose for 2 months did not show adverse effects and remained in good health throughout the experiment."( Safety studies evaluating the effect of mebendazole on liver function in dogs.
Marsboom, R; Van Cauteren, H; Vandenberghe, J; Will, JA, 1983
)
0.78
" At the end of the treatment we asked the parents if the children had presented any adverse events during the administration of the medication."( [Effectiveness and safety of mebendazole compared to nitazoxanide in the treatment of Giardia lamblia in children].
Cruz del Castillo, AH; Rodríguez-García, R; Rodríguez-Guzmán, LM,
)
0.42
" These studies have shown that monthly topical administration of selamectin is safe and highly effective in the treatment of naturally acquired ascarid and hookworm infections in cats."( Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients.
Benchaoui, HA; Boy, MG; Clemence, RG; Jernigan, AD; Rowan, TG; Six, RH; Smith, DG; Sture, GH; Thomas, CA; Watson, P, 2000
)
0.31
" Information about human and veterinary medical uses and adverse reactions is evaluated."( Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics.
Dayan, AD, 2003
)
0.69
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" No serious adverse events were reported or observed after treatment."( The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1-4 years in Uganda.
Kabatereine, NB; Namwanje, H; Olsen, A, 2011
)
0.6
" Cure rates and egg reduction rates were assessed, and adverse events were monitored after treatments."( Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths.
Duan, JH; Jiang, B; Liu, YC; Xiao, SH; Xu, LL; Zhang, HB; Zhang, LP; Zhou, XN; Zhu, SQ; Zhuang, SF, 2014
)
0.65
" Most adverse events were mild and transient."( Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths.
Duan, JH; Jiang, B; Liu, YC; Xiao, SH; Xu, LL; Zhang, HB; Zhang, LP; Zhou, XN; Zhu, SQ; Zhuang, SF, 2014
)
0.65
" sinensis as praziquantel with less adverse events, and achieved significantly higher cure rate in the treatment for hookworm than those of praziquantel and mebendazole."( Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths.
Duan, JH; Jiang, B; Liu, YC; Xiao, SH; Xu, LL; Zhang, HB; Zhang, LP; Zhou, XN; Zhu, SQ; Zhuang, SF, 2014
)
0.85
" About a fifth of the children reported adverse events, which were mainly mild."( Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled t
Albonico, M; Ali, SM; Alles, R; Ame, SM; Bogoch, II; Hattendorf, J; Huwyler, J; Keiser, J; Speich, B; Utzinger, J, 2015
)
0.65
" Our objective was to provide evidence on adverse events from anthelminthic use in early childhood."( Adverse Events from a Randomized, Multi-Arm, Placebo-Controlled Trial of Mebendazole in Children 12-24 Months of Age.
Casapía, M; Gyorkos, TW; Joseph, SA; Montresor, A; Pezo, L, 2016
)
0.67
" Although theoretically considered as safe during lactation, no studies have evaluated its potential adverse effects in infants of breastfeeding mothers."( Safety of Mebendazole Use During Lactation: A Case Series Report.
Berkovitch, M; Berlin, M; Cohen, R; Dinavitser, N; Karra, N; Koren, G, 2016
)
0.84
"Regardless of the treatment protocol used (single or repeated doses) mebendazole was well tolerated and was not associated with any adverse effects in infants of lactating mothers."( Safety of Mebendazole Use During Lactation: A Case Series Report.
Berkovitch, M; Berlin, M; Cohen, R; Dinavitser, N; Karra, N; Koren, G, 2016
)
1.07
" In rats, the No Observed Adverse Effect Level (NOAEL) was 5 mg (as base)/kg body weight/day (mg eq."( Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.
Bailey, G; Engelen, M; Lachau-Durand, S; Lammens, L; Lampo, A; van der Leede, BJ; Van Gompel, J, 2019
)
0.51
"Based on these results, in combination with previously described genotoxicity and reproductive toxicity data and the outcome of the preclinical efficacy studies, it was concluded that no flubendazole treatment regimen can be selected that would provide efficacy in humans at safe exposure."( Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.
Bailey, G; Engelen, M; Lachau-Durand, S; Lammens, L; Lampo, A; van der Leede, BJ; Van Gompel, J, 2019
)
0.51
" No severe adverse effects were observed."( A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer.
Alvfors, C; Fryknäs, M; Larsson, R; Loskog, A; Mansoori, S; Nygren, P, 2021
)
0.85

Pharmacokinetics

The pharmacokinetic evaluation of guar gum-based colon-targeted tablets of mebendazole against an immediate release tablet was carried out in human volunteers. Studies reported data on pharmacokinetics parameters for albENDazole or mebendedazole when taken with cimetidine, dexamethasone, ritonavir, phenytoin, carbamazepine, ivermectin, praziquantel, diethylcarbamazine, azithromycin, and levamisole.

ExcerptReferenceRelevance
" Theophylline pharmacokinetic parameters were significantly different during thiabendazole therapy."( Theophylline and antiparasitic drug interactions. A case report and study of the influence of thiabendazole and mebendazole on theophylline pharmacokinetics in adults.
Gannon, R; Schneider, D; Shore, E; Sweeney, K, 1990
)
0.49
"A sensitive and specific radioimmunoassay procedure was developed for mebendazole and flubendazole enabling a more thorough study of the systemic absorption and pharmacokinetic behaviour of the drugs."( The pharmacokinetics of mebendazole and flubendazole in animals and man.
Hendriks, R; Heykants, J; Michiels, M; van den Bossche, H, 1982
)
0.81
"A pharmacokinetic study of flubendazole was carried out, using a radioimmunological method, in patients with hydatid disease about to undergo surgery; there was no evidence of drug penetration into the walls or contents of the cysts."( [Pharmacokinetic study of flubendazole in human hydatid disease caused by Echinococcus granulosus. Preliminary results (author's transl)].
Coulaud, JP; Hay, JM; Manuel, C; Meulemans, A; Mohler, J; Saimot, AG, 1981
)
0.26
" This change was related to decreases in both the elimination from the pharmacokinetic compartment representing the reduced metabolite and the area under the curve of plasma metabolite concentration versus time."( Fasciola hepatica: mebendazole and thiabendazole pharmacokinetics in sheep.
Alvinerie, M; Biro-Sauveur, B; Coulet, M; Galtier, P; Sutra, JF, 1994
)
0.62
" Oral absorption is rapid compared with IM dosing; the absorption half-life (K01-HL) for the IM treatment is approximately 14 hr compared with 1 and 2 hr for the PO regimen of salt and free base forms, respectively."( Pharmacokinetics of UMF-078, a candidate antifilarial drug, in infected dogs.
Dzimianski, MT; Fleckenstein, L; McCall, JW; Theplertboon, R, 2000
)
0.31
"The pharmacokinetic evaluation of guar gum-based colon-targeted tablets of mebendazole against an immediate release tablet was carried out in human volunteers."( Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers.
Bhaskar, P; Dinesh Kumar, B; Karthikeyan, RS; Krishnaiah, YS; Satyanarayana, V; Veer Raju, P, 2003
)
0.77
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" For in vivo pharmacokinetic studies, further improvement and optimization of bioanalytical HPLC method in terms of sensitivity and selectivity was necessary."( Sensitive chiral high-performance liquid chromatographic determination of anthelmintic flubendazole and its phase I metabolites in blood plasma using UV photodiode-array and fluorescence detection Application to pharmacokinetic studies in sheep.
Krízová, V; Kubícek, V; Lamka, J; Nobilis, M; Skálová, L; Soukupová, M; Szotáková, B; Vybíralová, Z, 2008
)
0.35
" Low bioavailability and extensive first-pass metabolism make benzimidazoles prone to pharmacokinetic drug interactions."( Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.
Corti, N; Heck, A; Jetter, A; Pauli-Magnus, C; Rentsch, K; Stieger, B; Zingg, W, 2009
)
0.58
"The AUC(0-24) of benzimidazoles decreased after long-term use of ritonavir, while no changes in pharmacokinetic profiles were observed under short-term administration."( Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.
Corti, N; Heck, A; Jetter, A; Pauli-Magnus, C; Rentsch, K; Stieger, B; Zingg, W, 2009
)
0.58
" The information on FLU's pharmacokinetic behavior in animal species with forestomach (ruminants) has been limited although the use of FLU in these species could be beneficial."( Pharmacokinetics of flubendazole and its metabolites in lambs and adult sheep (Ovis aries).
Chládek, J; Cvilink, V; Krízová, V; Lamka, J; Nobilis, M; Prusková, L; Skálová, L; Szotáková, B, 2009
)
0.35
" The assay was successfully used to analyze human plasma samples in a pharmacokinetic study where levamisole was administered as a liniment."( A sensitive LC-MS/MS method for determination of levamisole in human plasma: application to pharmacokinetic study.
Ding, L; Li, Y; Liu, Y; Tong, L; Wang, J; Wang, Z; Wen, A; Yang, L, 2011
)
0.37
" Additionally, the comparative pharmacokinetic behaviour of FLBZ (and its metabolites) administered by the intraruminal (i."( Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution.
Alvarez, L; Ceballos, L; Lanusse, C; Moreno, L; Torrado, JJ, 2012
)
0.38
" However, oppositely to what was expected, the absorption-related pharmacokinetic parameters did not show any marked formulation-dependant effect."( Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution.
Alvarez, L; Ceballos, L; Lanusse, C; Moreno, L; Torrado, JJ, 2012
)
0.38
" Studies reported data on pharmacokinetic parameters for albendazole or mebendazole when taken with cimetidine, dexamethasone, ritonavir, phenytoin, carbamazepine, phenobarbital, ivermectin, praziquantel, diethylcarbamazine, azithromycin, and levamisole."( A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole.
Ensom, MH; Pawluk, SA; Roels, CA; Wilby, KJ, 2015
)
0.87
" Pharmacokinetic study: Balb/C mice received FLBZ (5 mg/kg) orally either alone or co-administered with NTZ (100 mg/kg)."( Combined flubendazole-nitazoxanide treatment of cystic echinococcosis: Pharmacokinetic and efficacy assessment in mice.
Carlos, L; Celina, E; Guillermo, D; Laura, C; Luis, A; Sergio, SB, 2015
)
0.42
" The goal of the current experimental work was to compare the pharmacokinetic plasma behavior of FLBZ, and its metabolites, formulated as either an aqueous hydroxypropyl- β -cyclodextrin-solution (HPBCD), an aqueous carboxymethyl cellulose-suspension (CMC) or a Tween 80-based formulation, in pigs."( Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule.
Alvarez, L; Ceballos, L; Geary, T; Lanusse, C; Mackenzie, C, 2015
)
0.42
" As this formulation results in improved systemic absorption, the pharmacokinetic and toxicological profile of the flubendazole ASD formulation have been assessed to ensure human safety before clinical trials could be initiated."( Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.
Bailey, G; Engelen, M; Lachau-Durand, S; Lammens, L; Lampo, A; van der Leede, BJ; Van Gompel, J, 2019
)
0.51
" Flubendazole, up to high peak plasma concentrations, does not induce Cmax related effects in CNS or cardiovascular system."( Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.
Bailey, G; Engelen, M; Lachau-Durand, S; Lammens, L; Lampo, A; van der Leede, BJ; Van Gompel, J, 2019
)
0.51

Compound-Compound Interactions

A randomized clinical trial was conducted to determine the safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and STH in children aged 1 to 4 years. No specific acceptability or safety studies have been published on this drug combination in younger children.

ExcerptReferenceRelevance
"The chemotherapeutic efficacy of mebendazole given in combination with Freund's complete adjuvant (FCA) against Brugia malayi in multimammate rat was evaluated."( Brugia malayi in Mastomys natalensis: efficacy of mebendazole in combination with Freund's complete adjuvant.
Chatterjee, RK; Murthy, PK; Tyagi, K, 1992
)
0.82
" Therefore, we attempted to evaluate the new treatment for the infection by mebendazole and its combination with thiabendazole."( [Treatment of strongyloidiasis with mebendazole and its combination with thiabendazole].
Arakkaki, T; Asato, R; Higashionna, A; Kadena, K; Kinjo, F; Kuniyoshi, T; Oyakawa, T; Saito, A; Shikiya, K, 1990
)
0.78
" In addition, although mebendazole has been extensively used together with praziquantel against infections with schistosomiasis and soil-transmitted helminthiasis (STH) in school-aged children, no specific acceptability or safety studies have been published on this drug combination in younger children."( The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1-4 years in Uganda.
Kabatereine, NB; Namwanje, H; Olsen, A, 2011
)
0.91
"A randomized clinical trial was conducted to determine the safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and STH in children aged 1 to 4 years."( The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1-4 years in Uganda.
Kabatereine, NB; Namwanje, H; Olsen, A, 2011
)
0.81
" A search of MEDLINE (1946 to October 2014), EMBASE (1974 to October 2014), International Pharmaceutical Abstracts (1970 to October 2014), Google, and Google Scholar was conducted for articles describing the pharmacokinetics of albendazole or mebendazole when given with other medications (and supplemented by a bibliographic review of all relevant articles)."( A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole.
Ensom, MH; Pawluk, SA; Roels, CA; Wilby, KJ, 2015
)
0.81
" Elevated plasma levels of albendazole sulfoxide, albendazole sulfone, and mebendazole in coadministrations are probably not mediated by CYP-based drug-drug interaction."( In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis.
Cowan, N; Keiser, J; Vargas, M, 2016
)
0.87
" These data suggest that MBZ, a well-tolerated off-patent approved drug, should be considered as a therapeutic option in combination with trametinib, for patients with NRASQ61mut or other non-V600E BRAF mutant melanomas."( The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.
Abdussamad, M; Atkins, MB; Byers, SW; Calvert, V; Chen, YS; Dakshanamurthy, S; Fang, HB; Gaur, A; Petricoin, EF; Rosenthal, DS; Simbulan-Rosenthal, CM; Zapas, J; Zhou, H, 2017
)
0.75

Bioavailability

Mebendazole (MBZ) is an extremely insoluble and therefore poorly absorbed drug. This lack of normalization was associated with lower bioavailability of the drug. The polymorphic forms of mebendazoles display significant differences in solubility and therapeutic efficacy.

ExcerptReferenceRelevance
" Mebendazole, a highly effective antihelmintic in enteric infections, is poorly absorbed by the gastrointestinal tract."( A clinical trial of mebendazole in the treatment of alveolar hydatid disease.
Davidson, M; Rausch, RL; Wilson, JF, 1978
)
1.49
" An almost complete loss of bioavailability after induction of the gut enzyme system by MC was observed."( Investigations on the biotransformation of mebendazole using an isolated perfused rat gut system.
Gottmanns, H; Kroker, R; Ungemach, FR, 1991
)
0.54
" Furthermore, greater bioavailability in rabbits was obtained after oral administration of the solid dispersion compared with the physical mixture."( Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol.
Chiba, Y; Iseki, K; Kohri, N; Miyazaki, K, 1991
)
0.53
"New formulations have been designed to increase the efficacy and bioavailability of the oral drugs mebendazole and nocodazole and were tested in CBA mice."( [Experimental chemotherapy of alveolar hydatid disease. 12. The efficacy of drug forms of mebendazole and nocodazole with high bioavailability].
Dobrotvorskiĭ, AE; Dzhabarova, VI; Krotov, AI,
)
0.57
"Increasing mebendazole bioavailability is one of the most important problems to be solved in echinococcosis chemotherapy."( [Clinical trial of the possibility of increasing the bioavailability of mebendazole using sunflower oil in echinococcosis].
Lur'e, AA; Shcherbakov, AM,
)
0.75
"Five volunteers, whose ages ranged between 37 and 64 years, took part in a crossover study to determine the pharmacokinetics and bioavailability of mebendazole in man following intravenous and oral administration of a tracer dose of [3H]-mebendazole."( The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.
Braithwaite, PA; Dawson, M; Roberts, MS; Watson, TR, 1985
)
0.71
" Oral administration of mebendazole as an oily suspension slightly enhances the bioavailability of the drug, however mebendazole is not absorbed following rectal administration."( The effect of dose form on the bioavailability of mebendazole in man.
Dawson, M; Watson, TR, 1985
)
0.83
" After oral administration, as a solution in aqueous dimethyl sulphoxide, a bioavailability of 53% was obtained."( The metabolic and pharmacokinetic disposition of mebendazole in the rat.
Allan, RJ; Watson, TR,
)
0.39
" These observations demonstrate the inefficacy of FZ in this series of 10 patients with alveolar echinococcosis, possibly related to the extremely poor bioavailability of FZ."( [Treatment of human alveolar echinococcosis with flubendazole. Clinical, morphological and immunological study].
Barale, T; Estavoyer, JM; Gillet, M; Lassègue, A; Miguet, JP; Minazzi, H; Vuitton, D, 1984
)
0.27
" The bioavailability of mebendazole from the solution was found to be 17%."( The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole.
Allan, RJ; Dawson, M; Watson, TR, 1982
)
0.83
" MBC and MEB are poorly soluble in water and therefore have a low bioavailability in vivo."( Clastogenic and aneugenic effects of three benzimidazole derivatives in the in vitro micronucleus test using human lymphocytes.
Elhajouji, A; Kirsch-Volders, M; Van Hummelen, P, 1995
)
0.29
" The results also indicated that lower drug absorption rate and thickening of the adventitia during longer disease course are the two major factors affecting the efficacy of Meb and Alb, hence suggesting that increase of Meb absorption may be expected to raise the therapeutic effect of the drug."( Effects of benzimidazole compounds on mice infected with secondary cysts of Echinococcus granulosus.
Chai, JJ; Jiao, W; Shen, BG; Xiao, SH; Yang, YQ; You, JQ, 1994
)
0.29
" The administration of ethanol did not affect the kinetic mechanism of the absorption process (simple diffusion) but the absorption rate decreased in all treatments except in 5% acute ethanol, presumably due to the improved solubility of the drugs."( Influence of ethanol on gastric absorption and metabolism of albendazole and mebendazole.
Alonso, ML; Alvarez, AI; Barrio, JP; del Estal, JL; Justel, A; Prieto, JG; Villaverde, C, 1994
)
0.52
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Colon-targeted tablets showed delayed t(max) and absorption time, and decreased C(max) and absorption rate constant when compared to the immediate release tablets."( Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers.
Bhaskar, P; Dinesh Kumar, B; Karthikeyan, RS; Krishnaiah, YS; Satyanarayana, V; Veer Raju, P, 2003
)
0.54
"The effect of solubilization by complexation with povidone on the oral bioavailability of three anthelmintic benzimidazole carbamate drugs: mebendazole (MBZ), albendazole (ABZ) and ricobendazole (RBZ), was studied in mice."( The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs.
Cuesta-Bandera, C; Daniel-Mwambete, K; Ponce-Gordo, F; Torrado, JJ; Torrado, S, 2004
)
0.53
" This lack of normalization was associated with lower bioavailability of mebendazole."( Immunosurveillance of alveolar echinococcosis by specific humoral and cellular immune tests: long-term analysis of the Swiss chemotherapy trial (1976-2001).
Ammann, RW; Eckert, J; Gottstein, B; Grimm, F; Renner, EC; Renner, EL, 2004
)
0.56
" Low bioavailability and extensive first-pass metabolism make benzimidazoles prone to pharmacokinetic drug interactions."( Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.
Corti, N; Heck, A; Jetter, A; Pauli-Magnus, C; Rentsch, K; Stieger, B; Zingg, W, 2009
)
0.58
" The polymorphic forms of mebendazole display significant differences in solubility and therapeutic efficacy and form C is preferred clinically due to its optimal bioavailability and reduced toxicity."( Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole.
Brits, M; de Villiers, MM; Liebenberg, W, 2010
)
0.87
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Its poor absorption from the gastrointestinal tract and low bioavailability aroused further research on new formulations of mebendazole to increase the bioavailability and improve the therapeutic efficacy."( [Research progress on the efficacy, metabolism and bioavailability of mebendazole in hydatid disease].
Liu, CS; Zhang, HB, 2009
)
0.79
"The aim of the present study is to explore the possibility to increase the efficacy of mebendazole (MBZ) against secondary cysts of Echinococcus granulosus harbored in mice by augmenting the solubility and bioavailability of the drug."( Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus.
Jiang, B; Liu, CS; Tao, Y; Wen, AD; Xue, J; Yao, JM; Zhang, HB, 2012
)
0.85
" Under the equal conditions of solubilization in vegetable oil, the biological activity and bioavailability of mebendazole were shown to increase to a much greater extent than those of albendazole."( [Comparative efficacy of albendazole and mebendazole oily suspensions in albino mice with experimental larval alveococcosis].
Kovalenko, FP; Kukhaleva, IV; Legon'kov, IuA; Shkoliar, NA,
)
0.61
"Mebendazole (MBZ) is an extremely insoluble and therefore poorly absorbed drug and the variable clinical results may correlate with blood concentrations."( Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose.
Bolás-Fernández, F; de la Torre-Iglesias, PM; García-Rodriguez, JJ; Torrado, G; Torrado, S; Torrado-Santiago, S, 2014
)
2.09
" We investigated the microparticulate structures that emerge spontaneously upon dispersion of an RDM in aqueous medium and elucidated their influence on dissolution, and also on their oral bioavailability and therapeutic efficiency using a murine model of infection with the nematode parasite Trichinella spiralis."( Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose.
Bolás-Fernández, F; de la Torre-Iglesias, PM; García-Rodriguez, JJ; Torrado, G; Torrado, S; Torrado-Santiago, S, 2014
)
0.65
"THE MBZ: L-HPC RDM might be an effective way of improving oral bioavailability and therapeutic activity using low doses of MBZ (5 mg/kg), which implies a low degree of toxicity for humans."( Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose.
Bolás-Fernández, F; de la Torre-Iglesias, PM; García-Rodriguez, JJ; Torrado, G; Torrado, S; Torrado-Santiago, S, 2014
)
0.65
"12-fold increase in the bioavailability of the drug."( Enhancing the bioavailability of mebendazole by integrating the principles solid dispersion and nanocrystal techniques, for safe and effective management of human echinococcosis.
Chaudhary, S; Garg, T; Goyal, AK; Murthy, RR; Rath, G, 2016
)
0.72
" However, a new formulation that provided sufficient bioavailability following oral administration could render FLBZ an effective treatment for onchocerciasis and LF."( In vitro flubendazole-induced damage to vital tissues in adult females of the filarial nematode Brugia malayi.
Agnew, DW; Geary, JF; Geary, TG; Mackenzie, CD; O'Neill, M, 2015
)
0.42
"This study investigates 3 amorphous technologies to improve the dissolution rate and oral bioavailability of flubendazole (FLU)."( Evaluation of Three Amorphous Drug Delivery Technologies to Improve the Oral Absorption of Flubendazole.
Backx, K; Boeykens, P; Bone, S; Brewster, ME; Ceulemans, J; Hillewaert, V; Jager, C; Kesselaers, E; Lachau-Durand, S; Mackie, C; Meurs, G; Novoa de Armas, H; Psathas, P; Smulders, S; Van Geel, K; Van Hove, B; Van Speybroeck, M; Verheyen, L; Verreck, G; Vialpando, M; Vodak, D; Voets, M; Weuts, I, 2016
)
0.43
" Unfortunately, the marketed formulation of FLBZ provides very limited oral bioavailability and parenteral administration is required for macrofilaricidal efficacy."( An In Vitro/In Vivo Model to Analyze the Effects of Flubendazole Exposure on Adult Female Brugia malayi.
DiCosty, U; Dzimianski, M; Geary, J; Geary, TG; Mackenzie, CD; Mansour, A; McCall, JW; McCall, SD; O'Neill, M, 2016
)
0.43
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The bioavailability of the anthelminthic flubendazole was remarkably enhanced in comparison with the pure crystalline drug by developing completely amorphous electrospun nanofibres with a matrix consisting of hydroxypropyl-β-cyclodextrin and polyvinylpyrrolidone."( Oral bioavailability enhancement of flubendazole by developing nanofibrous solid dosage forms.
Balogh, A; Boeykens, P; Borbás, E; Démuth, B; Galata, DL; Mackie, C; Marosi, G; Nagy, ZK; Pataki, H; Psathas, P; Van Assche, I; Van Hove, B; Verreck, G; Vialpando, M; Vigh, T, 2017
)
0.46
" Pharmacokinetic profiling of compounds 2 and 24 revealed low clearance and decent oral bioavailability (>70%)."( In vitro and in vivo efficacies of novel carbazole aminoalcohols in the treatment of cystic echinococcosis.
Duan, L; Li, J; Li, S; Wang, T; Wang, W; Yao, J; Zhang, W; Zheng, X, 2017
)
0.46
"Co-amorphous drug delivery systems are a promising approach to improve the dissolution rate and therefore potentially the oral bioavailability of poorly-water soluble drugs."( Aspartame as a co-former in co-amorphous systems.
Grohganz, H; Knuhtsen, A; Löbmann, K; Pedersen, DS; Rades, T; Schnitzkewitz, J; Wu, W, 2018
)
0.48
" For this purpose, an orally bioavailable amorphous solid dispersion (ASD) formulation of flubendazole was developed."( Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.
Bailey, G; Engelen, M; Lachau-Durand, S; Lammens, L; Lampo, A; van der Leede, BJ; Van Gompel, J, 2019
)
0.51
" In animals, flubendazole has good oral bioavailability from an ASD formulation ranging from 15% in dogs, 27% in rats to more than 100% in jirds."( Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.
Bailey, G; Engelen, M; Lachau-Durand, S; Lammens, L; Lampo, A; van der Leede, BJ; Van Gompel, J, 2019
)
0.51
" As part of an effort to stimulate the discovery and development of new macrofilaricides, particularly for onchocerciasis, research has recently been devoted to the development of new formulations that would afford high oral bioavailability of FBZ, paving the way for potential clinical development of this repurposed drug for the treatment of human filariases."( Flubendazole as a macrofilaricide: History and background.
Geary, TG; Mackenzie, CD; Silber, SA, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Flubendazole's potential use in clinical oncology will require further understanding of its mechanistic roles, range of inhibition of cancer types, capacity for adjunctive therapy and possible reformulation for enhanced solubility, bioavailability and potency."( Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent.
Khachigian, LM, 2021
)
0.62
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022
)
0.72
"Many lead compounds fail to reach clinical trials despite being potent because of low bioavailability attributed to their insufficient solubility making solubility a primary and crucial factor in early phase drug discovery."( Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Baidya, ATK; Das, B; Kumar, R; Mathew, AT; Yadav, AK, 2022
)
0.72
"Poorly water-soluble and poorly lipid-soluble drugs are called as "brick dust" and it is very hard for them to be formulated as some dosage form which can provide an effective bioavailability after oral administration."( Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: Disruption of high crystallinity by utilizing its counter ion.
Higaki, K; Inoue, T; Maruyama, M; Masuda, K; Okawa, S; Sumimoto, Y, 2022
)
0.98
"In this work, an important step is taken towards the bioavailability improvement of poorly water-soluble drugs, such as flubendazole (Flu), posing a challenge in the current development of many novel oral-administrable therapeutics."( Stable amorphous solid dispersion of flubendazole with high loading via electrospinning.
Becelaere, J; Borgmans, S; Creemers, K; De Clerck, K; Hoogenboom, R; Schoolaert, E; Van Den Broeck, E; Van Guyse, JFR; Van Speybroeck, V; Vanhoorne, V; Vergaelen, M; Vervaet, C, 2022
)
0.72
"Interest in mebendazole as an anticancer drug has stimulated research into new drug formulations to improve bioavailability and possibly reduce inter-individual variability in in-vivo drug levels, which may help its activity against cystic echinococcosis."( Medical management of cystic echinococcosis.
Chiodini, PL, 2023
)
1.29

Dosage Studied

Mebendazole (methyl-5-benzoylbenzimidazole-2-carbamate: Vermox), a broad spectrum anthelmintic, cured 22 (88%) children with symptomatic trichuriasis when given as a single 6-day course in a dosage of 100 mg twice daily. Albendazoles dosed at 3,8 mg/kg or 7,6 mg/ kilograms were totally ineffective against T. nana.

ExcerptRelevanceReference
" Levamisole at a dosage of 3 mg/kg daily for 8 days showed marked reduction in both microfilaria rate and microfilaria density and immediately thereafter mf-rate steadily increased almost up to pre-treatment level, the mf-density however showed only marginal increase."( Levamisole and mebendazole in the treatment of bancroftian infection.
Das, M; Narasimham, MV; Rao, CK; Roychowdhury, SP, 1978
)
0.61
"The effect of high dosage therapy with Mebendazole was studied in 5 patients with cystic echinococcosis and 2 patients with alveolar echinococcosis involving several organs."( Chemotherapy of echinococcosis with mebendazole: clinical observations of 7 patients.
Dietrich, M; Kern, P; Volkmer, KJ, 1979
)
0.8
"Mebendazole (methyl-5-benzoylbenzimidazole-2-carbamate: Vermox), a broad spectrum anthelmintic, cured 22 (88%) children with symptomatic trichuriasis when given as a single 6-day course in a dosage of 100 mg twice daily."( Further experience with mebendazole in the treatment of symptomatic trichuriasis in children.
Proctor, EM; Scragg, JN, 1978
)
2.01
" In the recommended dosage of 100 mg twice daily for 3 days mebendazole failed to achieve a cure rate of 95% to 100% reported in asymptomatic individuals and those with light infections of Trichuris trichiura."( Mebendazole in the treatment of severe symptomatic trichuriasis in children.
Proctor, EM; Scragg, JN, 1977
)
1.94
" The dosage for adults was 100 mg twice daily for 3 days and for children, 50 mg twice daily for 3 days."( Mebendazole in the treatment of helminthiasis.
Seah, SK, 1976
)
1.7
" The dosage for adults was 100 mg twice daily for 3 days, and for children, 50 mg twice daily for 3 days."( Mebendazole in the treatment of helminthiasis.
Seah, SK, 1976
)
1.7
" Various dosage schedules were evaluated."( Clinical trials with mebendazole a new broad spectrum anthelmintic.
Dalal, NJ; Enjetti, E; Vakil, BJ, 1975
)
0.57
"In mice infected with metacestodes of Taenia crassiceps, the following compounds were at least partially effective when injected intraperitoneally at the dosage indicated: cambendazole (500 mg/kg), mebendazole (6."( Effect of parenterally injected benzimidazole compounds on Echinococcus multilocularis and Taenia crassiceps metacestodes in laboratory animals.
Blair, LS; Campbell, WC; McCracken, RO, 1975
)
0.44
" Mebendazole was given in a dosage of 50 mg/kg body weight in repeated cycles of one month's duration followed by a treatment-free interval of two months."( [Long-term therapy of cystic liver echinococcosis with mebendazole].
Dietrich, M; Kern, P; Rippmann, K, 1992
)
1.44
" Better results were obtained when ABZ was administered at a dosage of 50 mg kg-1 day-1 for 3 consecutive days; the reduction in worm burden obtained with this treatment regimen was 50%."( Efficacy of albendazole and mebendazole against Hymenolepis microstoma and Hymenolepis diminuta.
Dronen, NO; Lipkowitz, KB; McCracken, RO, 1992
)
0.58
" fourth stage larvae (L4), pre-adult and adult stages were dosed with anthelminitics."( Response of pre-adult and adult stages of Trichuris muris to common anthelmintics in mice.
Bose, S; Deb, BN; Dhage, KR; Jones, MP; Rajasekariah, GR, 1991
)
0.28
" Mebendazole was administrated at the dosage of 30-50 mg/kg/day po for 30 days followed by a washout of 15 days, for a mean of 4 cycles (range 1-7) and 12 cycles (range 1-24) before and after surgery, respectively."( [Mebendazole in the therapy of hydatidosis].
Belicchi, M; Cartasegna, S; Costantino, D; Montorsi, M; Peta, M; Spiropoulos, J; Torzilli, G, 1991
)
2.1
" In the latter case, control was achieved by dosing either the ewes in the early part of the grazing season, or the lambs from June onwards."( Effectiveness of strategic anthelmintic dosing in controlling Haemonchus contortus infections in sheep in the United Kingdom.
Hunt, KR; Quick, JM; Taylor, MA; Wilson, CA, 1991
)
0.28
" Faecal examination for 5 months, the period from medication to dissection of rats, showed that L1 release ceased in all the rats of medicated groups by about 1 week after the termination of dosing and resumed 1-2 months later in 86% of the rats which were dissected at the end of experiments with the recovery of adult worms of both sexes."( Effect of flubendazole on the number of first-stage larvae of Angiostrongylus cantonensis released in the faeces of treated rats.
Maki, J; Yanagisawa, T, 1990
)
0.28
"A precise and accurate differential pulse polarographic method was developed for the determination of flubendazole in dosage forms without any prior extraction procedure of interference from the other stated ingredients."( Determination of flubendazole in pharmaceutical dosage forms by differential pulse polarography and UV spectroscopy.
Gratteri, P; La Porta, E; Mura, P; Papeschi, G; Pinzauti, S; Santoni, G, 1990
)
0.28
" Due to its lower cost and easier administration, the single dosage scheme is recommended for massive chemotherapy of geohelminthiasis in the community."( [Single dose mebendazole for the treatment of Trichuris trichiura and Necator americanus in chemotherapeutic control campaigns in the communities].
Finlay, CM; Gálvez Oviedo, D; Núñez Fernández, F; Sanjurjo González, ES,
)
0.5
" One hundred and ten patients with strongyloidiasis were treated with oral thiabendazole in a dosage of 50 mg/kg daily for two days; the other group of 41 patients was given mebendazole in a dosage of 10 mg/kg/day orally for five days."( [Comparative study of thiabendazole and mebendazole in strongyloidiasis].
Beus, A, 1989
)
0.74
" A chemoprophylaxis of the secondary abdominal echinococcosis was practised by means of Mebendazole (Vermox) in a dosage of 50 mg/kg body weight daily for 90 days."( [Chemoprevention of secondary abdominal echinococcosis--experimental study and clinical observation].
Jurukowa, D; Meinhard, P; Stojanow, G, 1989
)
0.5
"1% to 100% at the same dosage, when the dosage of 100mg/day for 30 days was given, the egg negative reversion rate for Trichuris trichiura was 97."( [Mebendazole-medicated-salt in the control of hookworm infection].
Gan, YC; He, QM; Huang, J; Li, SL; Meng, RB; Tang, CM; Wu, OL; Xie, CD; Xie, GG; Yao, RF, 1989
)
1.19
" Statistical confirmation was obtained that the use of this drug in different dose forms changed the rate of the response, suggesting that in the treatment of human hydatid disease caused by Echinococcus spp and cysticercosis caused by Taenia solium, the dosage form may be a vital factor in the drug's efficacy."( Significance of particle size of mebendazole in the treatment of tapeworm infections.
Gemmell, MA; Johnstone, PD; Oudemans, G, 1985
)
0.55
" No toxic or collateral effects, following the schedule of dosage and timing of the drugs used, were observed in these patients."( Combined medical and surgical therapy: a new approach to abdominal hydatidosis.
Castrini, G; Correnti, FS; Frattaroli, FM; Pappalardo, G; Reggio, D; Teggi, A, 1987
)
0.27
" Ivermectin as a paste formulation was given to sucking foals and pregnant mares in a single dosage of 200 micrograms/kg bodyweight by oral administration."( [Effectiveness of ivermectin in Strongyloides westeri cases in foals].
Hiepe, T; Köhler, M, 1986
)
0.27
" The drugs exhibited better anthelmintic efficacy in a divided dosing regimen than in a single dosing regimen."( Studies on anthelmintic effects of flubendazole and mebendazole on the rat lungworm Angiostrongylus cantonensis in mice and rats.
Maki, J; Yanagisawa, T, 1986
)
0.52
"Hamsters infected with laboratory-adapted preadult Necator americanus were dosed with 6 reference anthelmintics."( Response of preadult Necator americanus to some known anthelmintics in hamsters.
Bose, S; Deb, BN; Dhage, KR; Rajasekariah, GR, 1986
)
0.27
" nana were eliminated from mice by bithionol and mebendazole respectively, at the same dosage regimen."( Anthelmintic effects of bithionol, paromomycin sulphate, flubendazole and mebendazole on mature and immature Hymenolepis nana in mice.
Maki, J; Yanagisawa, T, 1985
)
0.75
"4% past formulation was given at a dosage of 22 mg/kg of body weight once a day for 2 or 3 consecutive days."( Anthelmintic efficacy of flubendazole paste against nematodes and cestodes in dogs and cats.
Hermans, L; Van der Flaes, L; Vanparijs, O, 1985
)
0.27
" The recommended dosage of mebendazole is 200 per day for 20 days for new cases and 30 days for relapses."( An obstinate case of intestinal capillariasis.
Alcantara, AK; Cross, JH; Uylangco, CV, 1985
)
0.57
"Critical controlled tests were performed in 157 sheep (8 experiments) and 34 cattle (2 experiments) to evaluate the anthelmintic activity of mebendazole suspension, administered intraruminally via a stomach tube at a dosage rate of 15 mg of mebendazole/kg of body weight, against induced infections of immature and adult stages of commonly encountered nematode parasites in South Africa."( Anthelmintic efficacy of mebendazole suspension against induced helminth infections in South African sheep and cattle.
Guerrero, J; Newcomb, K; Van der Westhuizen, B, 1984
)
0.77
" The daily dosage and other liver function tests seemed to be of minor importance in determining the plasma levels."( Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level.
Bircher, J; Witassek, F, 1983
)
0.53
" The area under the blood level versus time curve of mebendazole, in rats dosed with the prodrug, is more than twice that obtained after dosing rats with an equimolar amount of mebendazole."( 4-Amino-3-(3'-methoxycarbonyl-2'-thioureido)benzophenone, a prodrug of mebendazole.
Dawson, M; Watson, TR,
)
0.61
"Flubendazole has been given at a daily dosage of 50 mg/kg for 16 months (extremes 10 and 24 months) to 10 patients with hepatic alveolar echinococcosis."( [Treatment of human alveolar echinococcosis with flubendazole. Clinical, morphological and immunological study].
Barale, T; Estavoyer, JM; Gillet, M; Lassègue, A; Miguet, JP; Minazzi, H; Vuitton, D, 1984
)
0.27
" Irish Setters and Toy Poodles were dosed at 1, 3, and 5 times the therapeutic dose (22 mg/kg) of mebendazole for 17 days, without any effect on the liver."( Safety studies evaluating the effect of mebendazole on liver function in dogs.
Marsboom, R; Van Cauteren, H; Vandenberghe, J; Will, JA, 1983
)
0.75
" This dosage level indicated 100% efficacy against mature Ascaris suum, Oesophagostomum dentatum, Trichuris suis, and Metastrongylus apri."( Flubendazole: dose range and efficacy studies against common internal parasites of swine.
Becker, HN; Bradley, RE; Guerrero, J; Michael, BF; Newcomb, K, 1983
)
0.27
" The increase in the dosage allowed higher levels, as opposed to previous assertions."( [Treatment of alveolar echinococcosis with flubendazole. Pharmacological study (author's transl)].
Canton, P; Dureux, JB; Gérard, A; Roche, G, 1982
)
0.26
"Three metabolites of mebendazole were isolated from the bile of rats dosed with a mixture of mebendazole and pentadeuteromebendazole."( Identification of biliary metabolites of mebendazole in the rat.
Allan, RJ; Watson, TR, 1982
)
0.85
"A formulation of mebendazole was used to determine the optimal dosage level against induced and/or naturally occurring infections of Toxocara cati, Ancylostoma tubaeforme, and Taenia taeniaeformis in cats."( Anthelmintic activity of mebendazole against induced and naturally occurring helminth infections in cats.
Guerrero, J; London, CE; McCall, JW; Michael, B; Newcomb, K; Pancari, G; Roberson, EL, 1981
)
0.91
" Single oral doses of up to 5 times the effective dosage (39."( Clinical toxicosis and erythrocyte cholinesterase inhibition of trichlorfon combined with mebendazole in horses.
Gingerich, DA; Mia, AS, 1981
)
0.48
" The infected children in five primary schools, Po-Ai, Yung-Hua, Fu-Hsiao, Pao-Jeng and Hsin-Nan, were treated with one single dosage of 100 mg mebendazole."( [Results of school children with enterobiasis in Tainan city, treated with mebendazole].
Chang, JH; Chen, ER; Hu, SC; Huang, WH, 1995
)
0.72
" Drug blood levels were determined 1 and 4 hours after start of treatment and the dosage was then increased to 80-100 mg/kg daily."( [A small outbreak of trichinosis caused by imported smoked ham].
Brommer, M; Eichenlaub, D; Löscher, T; Nothdurft, HD, 1995
)
0.29
" The drug (paste) was administered and dosed according to the user's instruction."( [Efficacy of the oral antiparasitic mebendazole plus trichlorfon (telmin plus trichlorfon) against Gasterophilus in the horse].
Brocard, P; Pfister, K, 1993
)
0.56
" The game were extremely willing to ingest the drug applied with feed, the dosing schedule being confirmed."( [Effect of flubendazole on Muellerius capillaris in mouflon].
Klecá ková, J; Lamka, J; Vondrejc, M, 1996
)
0.29
" But since it is obvious from dose-response curves where the inflection point/threshold lies, it appears that the model might be picking up some irregularities (possibly due to experimental variability in the dose-response curve at concentrations greater than the threshold)."( Indication for thresholds of chromosome non-disjunction versus chromosome lagging induced by spindle inhibitors in vitro in human lymphocytes.
Elhajouji, A; Kirsch-Volders, M; Tibaldi, F, 1997
)
0.3
" The eggs from the lowest dosed group (3 mg kg-1 feed) did contain residues, but most of them were only slightly higher than the LOD."( Flubendazole residues in eggs after oral administration to laying hens: determination with reversed phase liquid chromatography.
Kan, CA; Keukens, HJ; Tomassen, MJ, 1998
)
0.3
" Cure rates increased both with dosage and duration, daily dosages of 60-70, 50 and 30-40 mg/kg curing 48%, 33% and 25%, respectively."( Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration.
Georgiev, P; Handjiev, S; Ivanov, A; Mechkov, G; Petkov, R; Todorov, T; Vachkov, P; Vutova, K, 1999
)
0.71
" In contrast to oral administration, IM dosing of UMF-078 provides sustained, relatively low plasma drug levels, with good tolerance and efficacy."( Pharmacokinetics of UMF-078, a candidate antifilarial drug, in infected dogs.
Dzimianski, MT; Fleckenstein, L; McCall, JW; Theplertboon, R, 2000
)
0.31
" Unit doses of selamectin (providing a minimum dosage of 6mgkg(-1)) were administered topically to the skin in a single spot at monthly intervals."( Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients.
Benchaoui, HA; Boy, MG; Clemence, RG; Jernigan, AD; Rowan, TG; Six, RH; Smith, DG; Sture, GH; Thomas, CA; Watson, P, 2000
)
0.31
" It is nearly insoluble in water and it influences not only the selection of the dosage form, but also its biological availability."( [Effect of temperature on drug solubility in complex formation of flubendazole and 2-hydroxypropyl-beta-cyclodextrin].
Rabisková, M; Sucman, E; Vetchý, D, 2000
)
0.31
" In light infection with Trichuris, albendazole administered at a dosage of 200 mg daily for 3 days showed a 48."( Strongyloides stercoralis infection and chronological changes of other soil-transmitted helminthiases in an endemic area of southern Thailand.
Anantaphruti, MT; Muennoo, C; Nuamtanong, S; Pubampen, S; Sanguankiat, S, 2000
)
0.31
" An experiment was conducted to evaluate the efficacy of mebendazole when administered at the dosage rate of 15-20 mg/kg body weight to gastrointestinal nematodes in captive gazelles."( Oral administration of mebendazole failed to reduce nematode egg shedding in captive African gazelles.
Abaigar, T; Cano, M; Espeso, G; Garijo, M; Ortiz, J; Ruiz de Ybáñez, MR, 2001
)
0.87
"), when treated with a dosage of 20 mg/kg for 5 consecutive days (99."( Efficacy of flubendazole and albendazole against Trichinella spiralis in mice.
Cho, SW; Chung, MS; Joo, KH; Kwon, HS; Quan, FS, 2001
)
0.31
" the same grade of damage was reached when incubating for a longer period at a low dosage or for a shorter period in medium containing a high amount (10 or 100 micro g/ml) of flubendazole."( In vitro studies on the effects of flubendazole against Toxocara canis and Ascaris suum.
Hanser, E; Hoeben, D; Mehlhorn, H; Vlaminck, K, 2003
)
0.32
" Since the dissolution of drugs from solid oral dosage forms can depend on the crystal form of the drug an attempt should be made while developing dissolution tests to set test parameters that are sensitive to changes in the crystal form."( Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences.
de Villiers, MM; Devarakonda, B; Liebenberg, W; Swanepoel, E, 2003
)
0.57
"Five red-legged pademelons (Thylogale stigmatica) were dosed orally with mebendazole at 50 mg/kg/d for 5 to 6 days."( Toxic effects of mebendazole at high dose on the haematology of red-legged pademelons (Thylogale stigmatica).
Berger, L; Johnson, PM; Skerratt, LF; Speare, R, 2004
)
0.89
") (4% suspension) administrations at the same dosage (5 mg/kg) with a 21-day washout period between treatments."( Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability.
Alvarez, L; Bruni, SS; Lanusse, C; Moreno, L; Mottier, L; Virkel, G, 2004
)
0.32
" Good dose-response data for the drugs tested was observed at the time of worm recovery from mice, with no worms recovered at the two highest concentrations of levamisole."( Efficacy of thiabendazole, mebendazole, levamisole and ivermectin against gullet worm, Gongylonema pulchrum: in vitro and in vivo studies.
Gotoh, H; Ikadai, H; Ishida, H; Kubota, H; Kudo, N; Oyamada, T, 2008
)
0.64
" In other group of mice, treatment with the same drugs and dosage was for seven days, starting at day 45 PI through the stage of encapsulating larvae (parenteral phase of infection)."( Study of the reproductive capacity of Trichinella spiralis recovered from experimentally infected mice under-dosed with albendazole or mebendazole.
Alvarez, N; de-la-Rosa, JL; Gomez-Priego, A, 2007
)
0.54
" Mebendazole aqueous suspensions display a controllable "delayed" or "hindered" sedimentation and a very easy redispersion which may contribute to the formulation of veterinary liquid dosage forms."( Role of the electrokinetic properties on the stability of mebendazole suspensions for veterinary applications.
Alvarez-Fuentes, J; Arias, JL; Cózar-Bernal, MJ; Fernández-Arévalo, M; Gallardo, V; Holgado, MA; Sáez-Fernández, E, 2010
)
1.52
" Subcellular fractions were prepared from liver and intestinal mucosa 24 h after the final dosage was administered."( Activities of biotransformation enzymes and flubendazole metabolism in lambs (Ovis aries): effect of gender and flubendazole therapy.
Bártíková, H; Krízová, V; Kubícek, V; Lamka, J; Skálová, L; Stepnicková, M; Szotáková, B,
)
0.13
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Combined surgery and continuous administration of albendazole at high dosage may allow alveolar echinococcosis patients to survive more than 30 years after diagnosis despite multi-organ involvement."( 30-yr course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient.
Bardonnet, K; Blagosklonov, O; Bresson-Hadni, S; Delabrousse, E; Grenouillet, F; Mantion, GA; Miguet, JP; Vuitton, DA, 2013
)
0.39
" Healthy animals of both species were allocated into four experimental groups of 44 animals each: FLBZ-CD oral and FLBZ-CDsc, treated with the FLBZ-CD formulation by the oral or subcutaneous routes, respectively; FLBZ-TWEENsc, dosed subcutaneously with the FLBZ-TWEEN formulation; and FLBZ-CMC oral, treated orally with the FLBZ suspension."( Exploring the potential of flubendazole in filariasis control: evaluation of the systemic exposure for different pharmaceutical preparations.
Alvarez, L; Ceballos, L; Geary, T; Lanusse, C; Mackenzie, C, 2014
)
0.4
" All samples underwent visual and physical inspection for labeling and packaging before physico-chemical quality testing and evaluated based on individual monographs in Pharmacopoeias for identification, assay/content, dosage uniformity, dissolution, disintegration and friability."( Quality of medicines commonly used in the treatment of soil transmitted helminths and giardia in ethiopia: a nationwide survey.
D'Hondt, M; De Spiegeleer, B; Deti, H; Duchateau, L; Levecke, B; Mekonnen, Z; Suleman, S; Vercruysse, J; Wynendaele, E; Zeleke, G, 2014
)
0.4
" Analysis of dose-response curves from the in vitro tests, using recently developed point of departure approaches, demonstrate that the aneugenic potency of flubendazole is very similar to related anti-parasitic benzimidazoles, including albendazole, which is used in mass drug administration programmes to combat endemic filarial diseases."( Genotoxicity of flubendazole and its metabolites in vitro and the impact of a new formulation on in vivo aneugenicity.
Evans, DB; Johnson, GE; Scandale, I; Tweats, DJ; Whitwell, J, 2016
)
0.43
" One group was untreated control (C-group) and the others were treated using a paste formulation of MBZ administered per os at the manufacturer's recommended horse dosage of 10 mg/kg body weight (MBZ 1) and at the double horse dosage 20 mg/kg body weight (MBZ 2)."( Plasma disposition, milk excretion and parasitological efficacy of mebendazole in donkeys naturally infected by Cyathostominae.
Aksit, D; Buono, F; Fagiolo, A; Gokbulut, C; Mariani, U; Roncoroni, C; Rufrano, D; Santoro, M; Veneziano, V, 2016
)
0.67
" All formulations were dosed to rats at 20 mg/kg in suspension."( Evaluation of Three Amorphous Drug Delivery Technologies to Improve the Oral Absorption of Flubendazole.
Backx, K; Boeykens, P; Bone, S; Brewster, ME; Ceulemans, J; Hillewaert, V; Jager, C; Kesselaers, E; Lachau-Durand, S; Mackie, C; Meurs, G; Novoa de Armas, H; Psathas, P; Smulders, S; Van Geel, K; Van Hove, B; Van Speybroeck, M; Verheyen, L; Verreck, G; Vialpando, M; Vodak, D; Voets, M; Weuts, I, 2016
)
0.43
" Sample information was recorded and encompassed trade name, active ingredient name, manufacturer's name and full address, labeled medicine strength, dosage form, number of units per container, dosage statement, batch/lot number, manufacturing and expiry dates, storage information and presence of leaflets/package insert."( Quality of anthelminthic medicines available in Jimma Ethiopia.
Belew, S; D'Hondt, M; De Spiegeleer, B; Duchateau, L; Kosgei, A; Suleman, S; Wynendaele, E, 2018
)
0.48
" Systemic exposures of FBZ/FBZ metabolites achieved following dosing were measured by pharmacokinetic (PK) bioanalysis."( Short-course, oral flubendazole does not mediate significant efficacy against Onchocerca adult male worms or Brugia microfilariae in murine infection models.
Akumtoh, DN; Aljayyoussi, G; Baeten, B; Chounna, PWN; Chunda, VC; Engelen, M; Fombad, FF; Gandjui, NVT; Lachaud, S; Metuge, HM; Ndzeshang, BL; Njouendou, AJ; Pionnier, N; Quirynen, L; Sjoberg, HT; Steven, A; Taylor, MJ; Tayong, DB; Tekle, F; Turner, JD; Wanji, S; Ward, SA, 2019
)
0.51
" In summary, oral doses of ASD formulated FBZ did not significantly reduce total worm burden but longer treatments, extended takedown times or a second dosing regimen, may decrease female fecundity and the number of mf shed by female worms."( Efficacy of subcutaneous doses and a new oral amorphous solid dispersion formulation of flubendazole on male jirds (Meriones unguiculatus) infected with the filarial nematode Brugia pahangi.
Baeten, B; Beerntsen, B; Bulman, CA; Engelen, M; Fischer, C; Gut, J; Ibiricu Urriza, I; Lachau-Durand, S; Lim, KC; Lustigman, S; Quirynen, L; Sakanari, J; Tekle, F, 2019
)
0.51
" Due to heterogeneity in terms of study design, sample size, deworming drug, dosage and outcomes measured, data from these studies could not be pooled."( Systematic review of exposure to albendazole or mebendazole during pregnancy and effects on maternal and child outcomes, with particular reference to exposure in the first trimester.
Gyorkos, TW; St-Denis, K, 2019
)
0.77
" Given these observations, the aims of this study were to investigate safety and efficacy of individualized dosed mebendazole in the cancer indication."( A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer.
Alvfors, C; Fryknäs, M; Larsson, R; Loskog, A; Mansoori, S; Nygren, P, 2021
)
1.06
"Poorly water-soluble and poorly lipid-soluble drugs are called as "brick dust" and it is very hard for them to be formulated as some dosage form which can provide an effective bioavailability after oral administration."( Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: Disruption of high crystallinity by utilizing its counter ion.
Higaki, K; Inoue, T; Maruyama, M; Masuda, K; Okawa, S; Sumimoto, Y, 2022
)
0.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antinematodal drugA substance used in the treatment or control of nematode infestations.
tubulin modulatorAny substance that interacts with tubulin to inhibit or promote polymerisation of microtubules.
microtubule-destabilising agentAny substance that interacts with tubulin to inhibit polymerisation of microtubules.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (61)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency5.49500.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.59560.006038.004119,952.5996AID1159521
SMAD family member 2Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346859
Fumarate hydrataseHomo sapiens (human)Potency18.65480.00308.794948.0869AID1347053
GALC proteinHomo sapiens (human)Potency0.631028.183828.183828.1838AID1159614
PPM1D proteinHomo sapiens (human)Potency2.33620.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency26.83250.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency0.35050.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency1.38650.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency5.13650.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.51540.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency1.97830.00137.762544.6684AID914; AID915
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency29.84930.000657.913322,387.1992AID1259377; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency4.46500.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.54810.01237.983543.2770AID1346984
EWS/FLI fusion proteinHomo sapiens (human)Potency0.77180.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.28560.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency10.24830.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency2.26140.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency3.80680.001530.607315,848.9004AID1224841; AID1224842; AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency1.05900.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency4.61410.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.52910.000229.305416,493.5996AID743069; AID743075
GVesicular stomatitis virusPotency10.96400.01238.964839.8107AID1645842
polyproteinZika virusPotency18.65480.00308.794948.0869AID1347053
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.33780.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency4.20030.000723.06741,258.9301AID743085; AID743122
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency9.00280.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency0.22390.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency49.19400.039147.5451146.8240AID1224845
cytochrome P450 2C9 precursorHomo sapiens (human)Potency1.58490.00636.904339.8107AID883
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.33360.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency11.88320.037617.082361.1927AID1259364; AID1259388
huntingtin isoform 2Homo sapiens (human)Potency5.62340.000618.41981,122.0200AID1688
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency15.84890.65619.452025.1189AID927
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency3.75750.000627.21521,122.0200AID743219
gemininHomo sapiens (human)Potency0.39690.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency8.03600.005612.367736.1254AID624032; AID624044
lethal factor (plasmid)Bacillus anthracis str. A2012Potency2.51190.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.89130.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency3.89200.00339.158239.8107AID1347407; AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency0.18720.002319.595674.0614AID651631; AID720552
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency1.58490.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency6.30960.009610.525035.4813AID1479145
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency15.84891.584913.004325.1189AID927
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency28.18381.000010.475628.1838AID1457
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency3.08310.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency3.20130.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)15.50000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Tyrosine-protein kinase ABL1Homo sapiens (human)IC50 (µMol)5.00000.00010.712810.0000AID672953
Tyrosine-protein kinase ABL1Homo sapiens (human)Ki4.60000.00021.399610.0000AID660980
Methionine aminopeptidaseEscherichia coli K-12IC50 (µMol)10.00000.47203.50775.0000AID259066
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)IC50 (µMol)10.00000.00020.533510.0000AID672954
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)Ki10.00000.00000.18970.8200AID660979
Vascular endothelial growth factor receptor 2Homo sapiens (human)IC50 (µMol)5.56670.00000.48308.8000AID1846062; AID697541; AID697542
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00051.33138.0000AID259066
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Calmodulin-domain protein kinase 1Toxoplasma gondiiIC50 (µMol)0.67000.23000.45000.6700AID672956
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (504)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of phospholipase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
neural tube closureTyrosine-protein kinase ABL1Homo sapiens (human)
B-1 B cell homeostasisTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
B cell proliferation involved in immune responseTyrosine-protein kinase ABL1Homo sapiens (human)
transitional one stage B cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
mismatch repairTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of DNA-templated transcriptionTyrosine-protein kinase ABL1Homo sapiens (human)
autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
DNA damage responseTyrosine-protein kinase ABL1Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
associative learningTyrosine-protein kinase ABL1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
post-embryonic developmentTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
cerebellum morphogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
microspike assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of endocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
neuron differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of axon extensionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of microtubule polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of Cdc42 protein signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of interleukin-2 productionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of osteoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
response to endoplasmic reticulum stressTyrosine-protein kinase ABL1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein modification processTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
signal transduction in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of vasoconstrictionTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase ABL1Homo sapiens (human)
alpha-beta T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of fibroblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
spleen developmentTyrosine-protein kinase ABL1Homo sapiens (human)
thymus developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
activated T cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
neuromuscular process controlling balanceTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of oxidoreductase activityTyrosine-protein kinase ABL1Homo sapiens (human)
neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
myoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of stress fiber assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
establishment of localization in cellTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrial depolarizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of focal adhesion assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cardiac muscle cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
neuroepithelial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase ABL1Homo sapiens (human)
ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
DNA conformation changeTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
response to epinephrineTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of protein serine/threonine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of dendrite developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of long-term synaptic potentiationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of hematopoietic stem cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of extracellular matrix organizationTyrosine-protein kinase ABL1Homo sapiens (human)
podocyte apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to dopamineTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of establishment of T cell polarityTyrosine-protein kinase ABL1Homo sapiens (human)
DN4 thymocyte differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein localization to cytoplasmic microtubule plus-endTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of microtubule bindingTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of modification of synaptic structureTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of blood vessel branchingTyrosine-protein kinase ABL1Homo sapiens (human)
activation of protein kinase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of Wnt signaling pathway, planar cell polarity pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell motilityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of endothelial cell apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of T cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
proteolysisMethionine aminopeptidaseEscherichia coli K-12
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
primary ovarian follicle growthProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of cytokine productionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
learning or memoryProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mechanical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to acidic pHProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of gene expressionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of glucose metabolic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein processingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
skeletal muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of smooth muscle cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
macroautophagyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
forebrain developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
T cell costimulationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of protein-containing complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein destabilizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to nutrient levelsProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to insulin stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of integrin activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of toll-like receptor 3 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
adherens junction organizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
substrate adhesion-dependent cell spreadingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of dephosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of hippo signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intracellular signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
entry of bacterium into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
osteoclast developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ERBB2 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
angiotensin-activated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
odontogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of vascular permeabilityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stress fiber assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transcytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Notch signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Ras protein signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein autophosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
oogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
leukocyte migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of small GTPase mediated signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mineralocorticoidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
myoblast proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to electrical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of mitochondrial depolarizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomerase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
uterus developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
branching involved in mammary gland duct morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell projection assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intestinal epithelial cell developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
interleukin-6-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hydrogen peroxideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to interleukin-1Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to lipopolysaccharideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to peptide hormone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to progesterone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fatty acidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hypoxiaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fluid shear stressProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of podosome assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
DNA biosynthetic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of heart rate by cardiac conductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein localization to nucleusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of TORC1 signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to prolactinProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of male germ cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ovarian follicle developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of lamellipodium morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor-beta signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of early endosome to late endosome transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of anoikisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of caveolin-mediated endocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
innate immune responseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
symbiont entry into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
branching involved in blood vessel morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of macroautophagyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial depolarizationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial fissionVascular endothelial growth factor receptor 2Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
ovarian follicle developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell maturationVascular endothelial growth factor receptor 2Homo sapiens (human)
endocardium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of cell shapeVascular endothelial growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of gene expressionVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of BMP signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
embryonic hemopoiesisVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor-2 signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
surfactant homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of neuron apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
cell fate commitmentVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
post-embryonic camera-type eye morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of positive chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of focal adhesion assemblyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 2Homo sapiens (human)
calcium ion homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
blood vessel endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular wound healingVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
semaphorin-plexin signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of hematopoietic progenitor cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of bone developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to hydrogen sulfideVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of endothelial cell apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (135)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
supercoiled DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
magnesium ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
four-way junction DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
bubble DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ABL1Homo sapiens (human)
DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
transcription coactivator activityTyrosine-protein kinase ABL1Homo sapiens (human)
actin monomer bindingTyrosine-protein kinase ABL1Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase C bindingTyrosine-protein kinase ABL1Homo sapiens (human)
protein bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ATP bindingTyrosine-protein kinase ABL1Homo sapiens (human)
kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
SH3 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
syntaxin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
manganese ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
SH2 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
mitogen-activated protein kinase bindingTyrosine-protein kinase ABL1Homo sapiens (human)
proline-rich region bindingTyrosine-protein kinase ABL1Homo sapiens (human)
delta-catenin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
sequence-specific double-stranded DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
aminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
initiator methionyl aminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
ferrous iron bindingMethionine aminopeptidaseEscherichia coli K-12
metalloexopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
metal ion bindingMethionine aminopeptidaseEscherichia coli K-12
metalloaminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
protein kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein kinase C bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
insulin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase activator activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
enzyme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
heme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nuclear estrogen receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
SH2 domain bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transmembrane transporter bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cadherin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATPase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phosphoprotein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
BMP receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
connexin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
scaffold protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
integrin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
coreceptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
identical protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
cadherin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
Hsp90 protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (79)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
ruffleTyrosine-protein kinase ABL1Homo sapiens (human)
nucleusTyrosine-protein kinase ABL1Homo sapiens (human)
nucleoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
nucleolusTyrosine-protein kinase ABL1Homo sapiens (human)
cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrionTyrosine-protein kinase ABL1Homo sapiens (human)
cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeletonTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear bodyTyrosine-protein kinase ABL1Homo sapiens (human)
dendriteTyrosine-protein kinase ABL1Homo sapiens (human)
growth coneTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear membraneTyrosine-protein kinase ABL1Homo sapiens (human)
neuronal cell bodyTyrosine-protein kinase ABL1Homo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
postsynapseTyrosine-protein kinase ABL1Homo sapiens (human)
protein-containing complexTyrosine-protein kinase ABL1Homo sapiens (human)
plasma membraneTyrosine-protein kinase ABL1Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolMethionine aminopeptidaseEscherichia coli K-12
cytosolMethionine aminopeptidaseEscherichia coli K-12
podosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nucleoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
lysosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
late endosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytosolProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
actin filamentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
caveolaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell junctionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ruffle membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic growth coneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
membrane raftProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
extracellular exosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
synaptic membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
glutamatergic synapseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
postsynaptic specialization, intracellular componentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic filopodiumProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 2Homo sapiens (human)
nucleusVascular endothelial growth factor receptor 2Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
early endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
endoplasmic reticulumVascular endothelial growth factor receptor 2Homo sapiens (human)
Golgi apparatusVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
external side of plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
cell junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
membrane raftVascular endothelial growth factor receptor 2Homo sapiens (human)
anchoring junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
sorting endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (349)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID108415Filaricidal activity against Brugia malayi in Mastomys at a dosage of 200 mg/kg x 5 administered orally at a day of 81986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1369632Tmax in Beagle dog at 2.5 mg/kg, po by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID87114Anthelmintic activity against Ancylostoma ceylanicum in hamsters at a dose of 0.5x1 mg/kg administered perorally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1369603Cmax in CD1 mouse at 1.5 mg/kg, iv at 5 mins by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1215939Unbound intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1403146Disruption of microtubule dynamics in human PC3MLN4 cells at 1 uM after 48 hrs by immunofluorescence microscopic method2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID672954Inhibition of human SRC2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID1215957Drug metabolism in human liver cytosol assessed as reductive metabolite formation at 10 uM after 20.80 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID658935Aqueous solubility of the compound2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID1369613Volume of distribution in CD1 mouse at 1.5 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID43794Antifilarial activity (percent reduction of live Brugia pahangi at necropsy relative to controls) was evaluated at dose of 25 mg/kg/day administered subcutaneously1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Synthesis of potential antifilarial agents. 1-(5-Benzoylbenzimidazol-2-yl)-3-alkyl- and -arylureas.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID658937Apparent permeability from basolateral to apical side of human Caco2 cells at 100 uM up to 90 mins2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1215937Unbound intrinsic clearance in human intestinal cytosol at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID108432Filaricidal activity against Dipetalonema viteae in Mastomys at a dosage of 300 mg/kg x 5 administered orally at a day of 421986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1215945Metabolic stability in human intestinal S9 fraction assessed as compound remaining at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis in presence of NADH2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID681121TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID658931Antiparasitic activity against Giardia duodenalis IMSS:0989 after 48 hrs2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID139572Anthelmintic activity against Syphacia obvelata in mice at a dose of 50x1 mg/kg administered perorally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID108420Filaricidal activity against Brugia malayi in Mastomys at a dosage of 50 mg/kg x 5 administered intraperitoneally at a day of 81986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID672946Cytotoxicity against human HL60 cells after 48 to 72 hrs by Alamar blue assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID84178Anthelmintic activity against Ancylostoma ceylanicum in hamsters at a dose of 0.5x1 mg/kg administered perorally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1403133Cytotoxicity against human PC3 cells assessed as cell viability at 10 uM after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID672949Antiparasitic activity against Cryptosporidium parvum up to 1 uM2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID1215941Metabolic stability in human intestinal microsomes assessed as compound remaining at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1369625AUC (0 to t) in CD1 mouse brain at 30 mg/kg administered via oral gavage by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID293710Anthelmintic activity against Eudrilus sp. assessed as mean death time2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID187896Antitapeworm activity evaluated as(percent animal freed of worms) against Hymenolepis nana in rat (dose 400 mg/kg X 3)administered orally1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and anthelmintic activity of 5(6)-(benzimidazol-2-ylcarbamoyl) and (4-substituted piperazin-1-yl)benzimidazoles.
AID1403136Cytotoxicity against human A549 cells assessed as cell viability at 1 uM after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1320567Inhibition of porcine tubulin polymerization assessed as increase in duration of nucleation phase at 10 uM measured every 94 secs2016Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20
Antitumor Activity of Lankacidin Group Antibiotics Is Due to Microtubule Stabilization via a Paclitaxel-like Mechanism.
AID1369610AUC (0 to t) in Beagle dog at 0.3 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID697542Inhibition of VEGFR2 after 60 mins by electrophoretic mobility shift assay2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Predicting new indications for approved drugs using a proteochemometric method.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID101669Antifilarial activity (percent reduction of live Litomosoides carinii at necropsy relative to controls) was evaluated at dose of 1.56 mg/kg/day administered subcutaneously1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Synthesis of potential antifilarial agents. 1-(5-Benzoylbenzimidazol-2-yl)-3-alkyl- and -arylureas.
AID1369606Half life in Beagle dog at 0.3 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID259068Inhibition of Co2+ loaded MetAP expressed in Escherichia coli at 10 uM2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1403139Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1215944Intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1215950Metabolic stability in human intestinal cytosol at 200 nM after 30 mins in presence of menadione2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID101831Antifilarial activity against Litomosoides carinii infections in the Jird at dose 1.56 mg/kg administered subcutaneously1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Synthesis and antifilarial activity of N-[4-[[4-alkoxy-3-[(dialkylamino)methyl]phenyl]amino]- 2-pyrimidinyl]-N'-phenylguanidines.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID108405Filaricidal activity against Brugia malayi in Mastomys at a dosage of 50 mg/kg x 5 administered intraperitoneally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID87112Anthelmintic activity against Ancylostoma ceylanicum (hook worm) in hamsters at a dose of 1x 1 mg/kg administered perorally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID658938Efflux ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco2 cells at 100 uM up to 90 mins2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID293709Anthelmintic activity against Eudrilus sp. assessed as mean paralyzing time2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID259066Inhibition of Co2+ loaded MetAP expressed in Escherichia coli2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID660976Selectivity ratio of Ki for human ABL to Ki for N-terminal hexaHis-tagged Toxoplasma gondii CDPK12012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
AID1403150Antitumor activity against human PC3MLN4 cells xenografted in nude mouse assessed as reduction in tumor volume at 30 mg/kg, ip administered every other day 3 times per week for 2 weeks2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID108418Filaricidal activity against Brugia malayi in Mastomys at a dosage of 50 mg/kg x 5 administered intraperitoneally at a day of 421986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1403130Selectivity ratio of EC50 for cytotoxicity against human PC3M cells to EC50 for cytotoxicity against human PC3MLN4 cells2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1215956Drug metabolism in human liver microsomes assessed as hydrolyzed metabolite formation at 10 uM after 19.83 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID251378In vivo percentage Haemonchus contortus egg reduction in sheep at dose 20 mg/kg body weight2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis and anthelmintic activity of 7-substituted 3,4a-dimethyl-4a,5a,8a,8b-tetrahydro-6H-pyrrolo[3',4':4,5]furo[3,2-b]pyridine-6,8(7H)-diones.
AID1369605Cmax in Beagle dog at 0.3 mg/kg, iv at 5 mins by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1215943Metabolic stability in human intestinal S9 fraction assessed as compound remaining at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID192890Filaricidal activity against Litomosoides carinii in cotton rats at a dosage of 100 mg/kg x 5 administered intraperitoneally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1369618Oral bioavailability in CD1 mouse plasma at 30 mg/kg administered via gavage by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1369614Volume of distribution in Beagle dog at 0.3 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID697541Inhibition of VEGFR2-mediated angiogenesis in human HUVEC cells after 24 hrs by inverted photomicroscopic analysis2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Predicting new indications for approved drugs using a proteochemometric method.
AID195832Filaricidal activity against Litomosoides carinii in cotton rats at a dosage of 300 mg/kg x 5 administered orally at a day of 81986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1215961Drug metabolism in human intestinal S9 fraction assessed as reductive metabolite formation at 10 uM after 20.69 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1403138Cytotoxicity against human Calu1 cells assessed as reduction in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1215952Drug metabolism in human intestinal cytosol at 200 nM after 30 mins in presence of flufenamic acid2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID658932Apparent permeability from apical to basolateral side of human Caco2 cells at 100 uM up to 90 mins2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID658936Distribution coefficient, log D of the compound2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1743051Antigiardial activity against Giardia lamblia H/7 incubated for 48 hrs by microscopic method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1369617AUC (0 to t) in CD1 mouse plasma at 30 mg/kg administered via oral gavage by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID84177Anthelmintic activity against Ancylostoma ceylanicum in hamsters at a dose 1x 1 mg/kg administered perorally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215938Unbound intrinsic clearance in human liver cytosol at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID101672Antifilarial activity (percent reduction of live Litomosoides carinii at necropsy relative to controls) was evaluated at dose of 25 mg/kg/day administered subcutaneously1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Synthesis of potential antifilarial agents. 1-(5-Benzoylbenzimidazol-2-yl)-3-alkyl- and -arylureas.
AID1403142Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1403141Cytotoxicity against human PC3MLN4 cells assessed as reduction in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID672955Inhibition of Cryptosporidium parvum CDPK12012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID489469Inhibition of Escherichia coli MetAP at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID293731Anthelmintic activity against Pontoscolex corethrurus ICARBC 408 assessed as mean paralyzing time2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1192804Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID190242Anthelmintic activity against Hymenolepis nana in rats at a dose of 400x3 mg/kg administered perorally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1776204Inhibition of tubulin polymerization in asexual blood stage Plasmodium falciparum NF54
AID660978Inhibition of Cryptosporidium parvum CDPK1 by nonradioactive Kinaseglo luciferase assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID101688Antifilarial activity against Litomosoides carinii infections in the Jird at dose 25 mg/kg administered subcutaneously1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Synthesis and antifilarial activity of N-[4-[[4-alkoxy-3-[(dialkylamino)methyl]phenyl]amino]- 2-pyrimidinyl]-N'-phenylguanidines.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1369596Prodrug conversion in mouse liver microsomes assessed as mebendazole formation by measuring remaining parent drug at 10 uM measured at 60 mins by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID108434Filaricidal activity against Dipetalonema viteae in Mastomys at a dosage of 6.25 mg/kg x 5 administered subcutaneous at a day of 211986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1369624Tmax in CD1 mouse brain at 30 mg/kg administered via oral gavage by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1369597Prodrug conversion in naive mouse plasma assessed as mebendazole formation by measuring remaining parent drug at 10 uM measured at 60 mins by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1846063Antitumor activity in Ptch+/- p53-/- mutant mouse medulloblastoma allograft model assessed as increase in survival rate at 50 mg/kg, po QD relative to control (Rvb=75 days)2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1369616Tmax in CD1 mouse plasma at 30 mg/kg administered via oral gavage by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1403129Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID672953Inhibition of human ABL2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1403149Solubility in pH 7.4 PBS buffer after 120 hrs by HPLC-UV method2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID672945Cytotoxicity against human CRL8155 cells after 48 to 72 hrs by Alamar blue assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID108419Filaricidal activity against Brugia malayi in Mastomys at a dosage of 50 mg/kg x 5 administered intraperitoneally at a day of 631986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1403135Cytotoxicity against human A549 cells assessed as cell viability at 10 uM after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1743049Antigiardial activity against Giardia lamblia P1 incubated for 48 hrs by haemocytometric counting method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1369609AUC (0 to t) in CD1 mouse at 1.5 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID195827Filaricidal activity against Litomosoides carinii in cotton rats at a dosage of 10 mg/kg x 5 administered intraperitoneally at a day of 211986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1192802Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID681132TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID293729Anthelmintic activity against Megascoplex konkanensis ICARBC 211 assessed as mean paralyzing time2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID1403131Cytotoxicity against human PC3MLN4 cells assessed as cell viability at 10 uM after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID195829Filaricidal activity against Litomosoides carinii in cotton rats at a dosage of 10 mg/kg x 5 administered intraperitoneally at a day of 81986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID259067Inhibition of Mn2+ loaded MetAP expressed in Escherichia coli at upto 10 uM2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
AID1743093Half-life of the compound2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1743050Antigiardial activity against Giardia lamblia WB incubated for 48 hrs by microscopic method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID108421Filaricidal activity against Brugia malayi in Mastomys at a dosage of 50 mg/kg x 5 administered intraperitoneally at a day of 911986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID106806Inhibition of malate dehydrogenase (MDH) at 400 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1403148Thermodynamic solubility in pH 7.4 PBS buffer after 24 hrs by HPLC-UV method2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1369631Cmax in Beagle dog at 2.5 mg/kg, po measured at 2 hrs by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID108413Filaricidal activity against Brugia malayi in Mastomys at a dosage of 200 mg/kg x 5 administered orally at a day of 421986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1215936Unbound intrinsic clearance in human liver microsomes at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID672950Antiparasitic activity against Toxoplasma gondii up to 1 uM2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID108431Filaricidal activity against Dipetalonema viteae in Mastomys at a dosage of 300 mg/kg x 5 administered orally at a day of 211986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID660981Selectivity ratio of Ki for human ABL to Ki for Cryptosporidium parvum CDPK12012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1215959Drug metabolism in human liver S9 fraction assessed as reductive metabolite formation at 10 uM after 20.76 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1369640Oral bioavailability in human at 1.18 ug2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID108409Filaricidal activity against Dipetalonema viteae in Mastomys at a dosage of 300 mg/kg x 5 administered orally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID43795Antifilarial activity (percent reduction of live Brugia pahangi at necropsy relative to controls) was evaluated at dose of 6.25 mg/kg/day administered subcutaneously1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Synthesis of potential antifilarial agents. 1-(5-Benzoylbenzimidazol-2-yl)-3-alkyl- and -arylureas.
AID658934Lipophilicity, logkw of the compound by RP-HPLC analysis2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID660977Inhibition of N-terminal hexaHis-tagged Toxoplasma gondii CDPK1 expressed in Escherichia coli BL21* by nonradioactive Kinaseglo luciferase assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID108433Filaricidal activity against Dipetalonema viteae in Mastomys at a dosage of 300 mg/kg x 5 administered orally at a day of 81986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1369601Plasma concentration in CD1 mouse at 30 mg/kg administered single dose via oral gavage measured at 60 mins by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID658930Influx ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells at 100 uM up to 90 mins2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1403128Cytotoxicity against human PC3MLN4 cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1369611Clearance in CD1 mouse at 1.5 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1369634Oral bioavailability in Beagle dog at 2.5 mg/kg by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1215954Drug metabolism in human intestinal cytosol at 200 nM after 30 mins in presence of ondansetron2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID101673Antifilarial activity (percent reduction of live Litomosoides carinii at necropsy relative to controls) was evaluated at dose of 6.25 mg/kg/day administered subcutaneously1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Synthesis of potential antifilarial agents. 1-(5-Benzoylbenzimidazol-2-yl)-3-alkyl- and -arylureas.
AID108417Filaricidal activity against Brugia malayi in Mastomys at a dosage of 50 mg/kg x 5 administered intraperitoneally at a day of 211986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID195831Filaricidal activity against Litomosoides carinii in cotton rats at a dosage of 300 mg/kg x 5 administered orally at a day of 421986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1369608Tmax in Beagle dog at 0.3 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID108410Filaricidal activity against Dipetalonema viteae in Mastomys at a dosage of 6.25 mg/kg x 5 administered subcutaneous1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID101696Antifilarial activity against Litomosoides carinii infections in the Jird at dose 6.25 mg/kg administered subcutaneously1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Synthesis and antifilarial activity of N-[4-[[4-alkoxy-3-[(dialkylamino)methyl]phenyl]amino]- 2-pyrimidinyl]-N'-phenylguanidines.
AID1403143Cytotoxicity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1403144Cell cycle arrest in human PC3MLN4 cells assessed as accumulation at G2/M phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1403132Cytotoxicity against human PC3MLN4 cells assessed as cell viability at 1 uM after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1215958Drug metabolism in human liver S9 fraction assessed as hydrolyzed metabolite formation at 10 uM after 19.80 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1403147Kinetic solubility in pH 7.4 PBS buffer sonicated for 30 mins by HPLC-UV method2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1215940Unbound intrinsic clearance in human liver S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1355477Antiprotozoal activity against Tritrichomonas foetus KV12018Journal of natural products, 07-27, Volume: 81, Issue:7
Banksialactones and Banksiamarins: Isochromanones and Isocoumarins from an Australian Fungus, Aspergillus banksianus.
AID195828Filaricidal activity against Litomosoides carinii in cotton rats at a dosage of 10 mg/kg x 5 administered intraperitoneally at a day of 421986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1403151Toxicity in nude mouse xenografted with human PC3MLN4 cells assessed as reduction in body weight at 30 mg/kg, ip administered every other day 3 times per week for 2 weeks measured 3 times per week during compound dosing relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID108414Filaricidal activity against Brugia malayi in Mastomys at a dosage of 200 mg/kg x 5 administered orally at a day of 631986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1215960Drug metabolism in human intestinal cytosol assessed as reductive metabolite formation at 10 uM after 20.74 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID660980Inhibition of human ABL by radiometric assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
AID1320568Inhibition of porcine tubulin polymerization assessed as maximum growth rate at 10 uM measured every 94 secs (Rvb = 13 milliOD/min)2016Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20
Antitumor Activity of Lankacidin Group Antibiotics Is Due to Microtubule Stabilization via a Paclitaxel-like Mechanism.
AID192892Filaricidal activity against Litomosoides carinii in cotton rats at a dosage of 10 mg/kg x 5 administered intraperitoneally at a day of 421986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID108412Filaricidal activity against Brugia malayi in Mastomys at a dosage of 200 mg/kg x 5 administered orally at a day of 211986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID195830Filaricidal activity against Litomosoides carinii in cotton rats at a dosage of 300 mg/kg x 5 administered orally at a day of 211986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID108435Filaricidal activity against Dipetalonema viteae in Mastomys at a dosage of 6.25 mg/kg x 5 administered subcutaneous at a day of 421986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1192801Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1369607Tmax in CD1 mouse at 1.5 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1215948Unbound intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 30 to 60 mins by HPLC-MS/MS analysis in presence of NADPH2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID489473Inhibition of human MetAP1 at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID108436Filaricidal activity against Dipetalonema viteae in Mastomys at a dosage of 6.25 mg/kg x 5 administered subcutaneous at a day of 81986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID293732Anthelmintic activity against Pontoscolex corethrurus ICARBC 408 assessed as mean death time2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID1369598Solubility of the compound in 0.01 M PBS after 24 hrs by shake flask method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID337647Anthelmintic activity against Caenorhabditis elegans1994Journal of natural products, Oct, Volume: 57, Issue:10
Ellagitannins and complex tannins from Quercus petraea bark.
AID29363Dissociation constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID660979Inhibition of human SRC by radiometric assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
AID1403134Cytotoxicity against human PC3 cells assessed as cell viability at 1 uM after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID293730Anthelmintic activity against Megascoplex konkanensis ICARBC 211 assessed as mean death time2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID108404Filaricidal activity against Brugia malayi in Mastomys at a dosage of 200 mg/kg x 5 administered orally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID1866020Thermodynamic aqueous solubility of the compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID1403137Cytotoxicity against human NCI-H157 cells assessed as reduction in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1215946Intrinsic clearance in human intestinal S9 fraction at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis in presence of NADH2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1369633AUC (0 to t) in Beagle dog at 2.5 mg/kg, po by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID187890Antitapeworm activity evaluated as reduction of worms with scolices against Hymenolepis nana in rat ( dose 400 mg/kg X 3) administered orally1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and anthelmintic activity of 5(6)-(benzimidazol-2-ylcarbamoyl) and (4-substituted piperazin-1-yl)benzimidazoles.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1320569Inhibition of porcine tubulin polymerization assessed as decrease in final polymer mass at 10 uM measured every 94 secs2016Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20
Antitumor Activity of Lankacidin Group Antibiotics Is Due to Microtubule Stabilization via a Paclitaxel-like Mechanism.
AID1369612Clearance in Beagle dog at 0.3 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1215955Apparent permeability of the compound at 50 uM at pH 7.4 after 240 mins by PAMPA2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1215942Intrinsic clearance in human intestinal microsomes at 50 to 1000 nM after 60 mins by HPLC-MS/MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID672956Inhibition of Toxoplasma gondii CDPK12012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID43792Antifilarial activity (percent reduction of live Brugia pahangi at necropsy relative to controls) was evaluated at dose of 1.56 mg/kg/day administered subcutaneously1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Synthesis of potential antifilarial agents. 1-(5-Benzoylbenzimidazol-2-yl)-3-alkyl- and -arylureas.
AID489471Inhibition of Staphylococcus aureus MetAP at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1403140Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID1369595Prodrug conversion in mouse jejunum homogenate assessed as mebendazole formation by measuring remaining parent drug at 10 uM measured at 60 mins by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1369623Cmax in CD1 mouse brain at 30 mg/kg administered via oral gavage at 60 mins by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1369639Oral bioavailability in human at 1.7 ug2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID1369615Cmax in CD1 mouse plasma at 30 mg/kg administered via oral gavage at 60 mins by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID237429Partition coefficient (logP) (HPLC)2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis and anthelmintic activity of 7-substituted 3,4a-dimethyl-4a,5a,8a,8b-tetrahydro-6H-pyrrolo[3',4':4,5]furo[3,2-b]pyridine-6,8(7H)-diones.
AID1846062Inhibition of human VEGFR2 (789 to 1356 residues) assessed as reduction in autophosphorylation at Y1175 residues using poly (Glu4Tyr1) peptide and ATP as substrate incubated for 60 mins by ADP-Glo Kinase Assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1369604Half life in CD1 mouse at 1.5 mg/kg, iv by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID108416Filaricidal activity against Brugia malayi in Mastomys at a dosage of 200 mg/kg x 5 administered orally at a day of 911986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID139570Anthelmintic activity against Syphacia obvelata in mice at a dose of 100x1 mg/kg administered perorally1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Studies in potential filaricides. 18. Synthesis of 2,2'-disubstituted 5,5'-dibenzimidazolyl ketones and related compounds as potential anthelmintics.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID681130TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1369626Ratio of drug level in brain to plasma in CD1 mouse at 30 mg/kg administered via oral gavage by LC-MS/MS method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.
AID489475Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1645871NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,851)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990698 (37.71)18.7374
1990's357 (19.29)18.2507
2000's326 (17.61)29.6817
2010's347 (18.75)24.3611
2020's123 (6.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.81 (24.57)
Research Supply Index7.73 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index190.58 (26.88)
Search Engine Supply Index2.95 (0.95)

This Compound (71.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials184 (8.81%)5.53%
Reviews129 (6.18%)6.00%
Case Studies424 (20.30%)4.05%
Observational2 (0.10%)0.25%
Other1,350 (64.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of a Single-dose Regimen and a Multi-dose Regimen of Mebendazole Against Hookworm Infections in School Children: a Randomized Controlled Trial [NCT03245398]Phase 4186 participants (Actual)Interventional2017-07-25Completed
Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer [NCT03925662]Phase 340 participants (Anticipated)Interventional2019-04-01Recruiting
The Efficacy of a Single-dose Mebendazole Against Soil-transmitted Helminths in School Children [NCT01379326]Phase 4250 participants (Actual)Interventional2011-12-31Completed
Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis [NCT02385058]Phase 4100 participants (Actual)Interventional2005-10-31Completed
Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care [NCT01314937]Phase 41,760 participants (Anticipated)Interventional2011-09-30Completed
A Single-Dose, Open-Label, Randomized, 2-Way Crossover Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Subjects [NCT02051738]Phase 11 participants (Actual)Interventional2014-02-28Completed
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas [NCT01837862]Phase 1/Phase 236 participants (Anticipated)Interventional2013-10-22Recruiting
An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive [NCT01173562]Phase 3397 participants (Actual)Interventional2010-02-28Completed
Efficacy and Safety of a Single-dose Regimen and a Multi-dose Regimen of Mebendazole Against Hookworm Infections in Children and Adolescents in Ghana: a Randomized Controlled Trial [NCT03261596]Phase 40 participants (Actual)Interventional2017-09-30Withdrawn(stopped due to In light of new evidence, the decision was made by the sponsor to not proceed.)
A Phase 2a TDM-guided Clinical Study on the Safety and Efficacy of Mebendazole in Patients With Advanced Gastrointestinal Cancer or Cancer of Unknown Origin [NCT03628079]Phase 1/Phase 211 participants (Actual)Interventional2018-05-25Terminated(stopped due to Lack of effect)
A Non Randomised, Non Blinded Real World Trial of the Safety, Tolerability and Effectiveness of Metabolic Medicines for the Treatment of Cancer Compared Against Matched Controls [NCT02201381]Phase 30 participants (Actual)Interventional2022-05-23Withdrawn(stopped due to Prospective recruitment not possible)
A Study on the Effectiveness of IFA Supplementation, Deworming, and Nutrition Education in Addressing Anemia Among Adolescent Girls in Two Counties in Liberia [NCT05073562]0 participants (Actual)Interventional2021-10-31Withdrawn(stopped due to Change in funding availability)
Establishing a Surveillance System to Monitor the Global Patterns of Drug Efficacy and Emergence of Anthelmintic Resistance in Soil-transmitted Helminth Programs [NCT04177654]9,457 participants (Actual)Observational2019-05-15Completed
The Efficacy of 5 Anthelmintic Regimes Against T. Trichiura Infections in Schoolchildren in Jimma, Ethiopia [NCT01327469]Phase 42,250 participants (Actual)Interventional2010-12-31Completed
RDD1609 as a Treatment for Idiopathic Pruritus Ani: A Randomized Double Blinded Placebo Controlled Crossover Study [NCT03757403]Phase 20 participants (Actual)Interventional2020-05-01Withdrawn(stopped due to Covid-19)
Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Praziquantel Study [NCT01050374]650 participants (Anticipated)Interventional2007-10-31Completed
Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Study on Trichuris Trichiura. [NCT01050452]750 participants (Anticipated)Interventional2007-10-31Completed
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors [NCT02644291]Phase 116 participants (Actual)Interventional2016-05-31Completed
Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon [NCT04326868]Phase 4255 participants (Actual)Interventional2019-11-11Completed
Phase I Study of Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide [NCT01729260]Phase 124 participants (Actual)Interventional2013-04-04Completed
Different Drug Combinations Against Hookworm Infection in School-aged Children in the Lao People's Democratic Republic, a Single Blind, Randomised Controlled Trial [NCT03278431]Phase 4420 participants (Actual)Interventional2017-09-27Completed
Evaluation of Anthelminthics and Multivitamins for Treatment of Severe Anemia in Pregnant Women and Children 6-24 Months of Age in Pakistan [NCT00116493]Phase 31,009 participants (Actual)Interventional2004-04-30Completed
Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections [NCT01350271]Phase 3214 participants (Actual)Interventional2011-05-31Completed
Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors [NCT04771520]Phase 250 participants (Anticipated)Interventional2021-01-20Recruiting
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis [NCT01905423]17,108 participants (Actual)Observational2011-05-31Completed
Efficacy and Safety of a New Chewable Tablet of Mebendazole Versus the Swallowable, Standard Tablet of Mebendazole Against Hookworm Infections in Children: a Randomized Controlled Trial [NCT03995680]Phase 2397 participants (Actual)Interventional2019-07-12Completed
A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoid [NCT02034162]Phase 3295 participants (Actual)Interventional2014-12-31Completed
Preventing Unnecessary Blood Transfusions in Pregnant Women in Africa Through Effective Primary Health Care [NCT00148629]Phase 32,500 participants Interventional2004-04-30Active, not recruiting
To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma. [NCT04443049]170 participants (Anticipated)Interventional2020-07-10Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01350271 (3) [back to overview]Faecal Egg Count Reduction 1 (FECR1)
NCT01350271 (3) [back to overview]Faecal Egg Count Reduction 2 (FECR2)
NCT01350271 (3) [back to overview]Cure Rate
NCT01905423 (6) [back to overview]Prevalence of Ascaris Infection
NCT01905423 (6) [back to overview]Prevalence of Circulating Filarial Antigen in Blood as Determined by ICT Card Test
NCT01905423 (6) [back to overview]Prevalence of Hookworm Infection
NCT01905423 (6) [back to overview]Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood
NCT01905423 (6) [back to overview]Prevalence of Positive Brugia Rapid Antifilarial Antibody Tests
NCT01905423 (6) [back to overview]Prevalence of Trichuris Infection
NCT02034162 (10) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Mebendazole
NCT02034162 (10) [back to overview]Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours (AUC8h) of Mebendazole
NCT02034162 (10) [back to overview]Area Under the Plasma Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-last) of Mebendazole
NCT02034162 (10) [back to overview]Cure Rate for Ascaris Lumbricoides at the End of Double-blind Treatment Period
NCT02034162 (10) [back to overview]Cure Rate for Trichuris Trichiura at the End of Double-blind Treatment Period
NCT02034162 (10) [back to overview]Egg Count Reduction Rate (Percent) for Ascaris Lumbricoides Infestation at the End of Double-blind Treatment Period
NCT02034162 (10) [back to overview]Egg Count Reduction Rate (Percent) for Trichuris Trichiura Infestation at the End of Double-blind Treatment Period
NCT02034162 (10) [back to overview]Maximum Plasma Concentration (Cmax) of Mebendazole
NCT02034162 (10) [back to overview]Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Double-Blind Treatment Period
NCT02034162 (10) [back to overview]Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Open-Label Treatment Period
NCT03245398 (9) [back to overview]Arithmetic ERR of Both Mebendazole Regimens Against Trichuris Trichiura
NCT03245398 (9) [back to overview]Arithmetic ERR of the Two Regimens of Mebendazole Against Hookworm
NCT03245398 (9) [back to overview]CR of Both Mebendazole Regimens Against Trichuris Trichiura
NCT03245398 (9) [back to overview]Cure Rate (CR) of Both Mebendazole Regimens Against Ascaris Lumbricoides
NCT03245398 (9) [back to overview]Cure Rate (CR) of Mebendazole Against Hookworm
NCT03245398 (9) [back to overview]Geometric ERR of Both Mebendazole Regimens Against Ascaris Lumbricoides.
NCT03245398 (9) [back to overview]Geometric ERR of Both Mebendazole Regimens Against Trichuris Trichiura
NCT03245398 (9) [back to overview]Geometric Mean Egg Reduction Rate (ERR) of the Two Regimens of Mebendazole Against Hookworm
NCT03245398 (9) [back to overview]Arithmetic ERR of Both Mebendazole Regimens Against Ascaris Lumbricoides
NCT03995680 (9) [back to overview]Arithmetic ERR of the Two Formulations of Mebendazole Against Hookworm
NCT03995680 (9) [back to overview]CR of Both Mebendazole Formulations Against Ascaris Lumbricoides
NCT03995680 (9) [back to overview]CR of Both Mebendazole Regimens Against Trichuris Trichiura
NCT03995680 (9) [back to overview]Cure Rate (CR) of Mebendazole Against Hookworm
NCT03995680 (9) [back to overview]Geometric ERR of Both Mebendazole Formulations Against Ascaris Lumbricoides.
NCT03995680 (9) [back to overview]Geometric ERR of Both Mebendazole Formulations Against Trichuris Trichiura
NCT03995680 (9) [back to overview]Geometric Mean Egg Reduction Rate (ERR) of the Two Formulations of Mebendazole Against Hookworm
NCT03995680 (9) [back to overview]Arithmetic ERR of Both Mebendazole Formulations Against Trichuris Trichiura
NCT03995680 (9) [back to overview]Arithmetic ERR of Both Mebendazole Formulations Against Ascaris Lumbricoides

Faecal Egg Count Reduction 1 (FECR1)

FECR1= {[(Arithmetic mean of pretreatment egg counts)-(arithmetic mean of posttreatment egg counts)]÷(arithmetic mean of pretreatment egg counts)}×100 (NCT01350271)
Timeframe: Two weeks

Interventionpercentage of eggs excreted (Number)
Placebo-6.6
Mebendazole Polymorph A and C 500 mg86.1
Mebendazole Polymorph C 500 mg84.5

[back to top]

Faecal Egg Count Reduction 2 (FECR2)

FECR2=〈Arithmetic mean {[(pretreatment egg count)-(posttreatment egg count)]÷(pretreatment egg count)}〉×100 (NCT01350271)
Timeframe: Two weeks

Interventionpercentage of eggs excreted (Mean)
Placebo-108.1
Mebendazole Polymorph A and C 500 mg66.2
Mebendazole Polymorph C 500 mg49.8

[back to top]

Cure Rate

Cure rate={(Number positive pretreatment - Number positive posttreatment)÷(Number positive pretreatment)}×100 (NCT01350271)
Timeframe: Two weeks

Interventionpercentage of participants (Number)
Placebo16.3
Mebendazole Polymorph A and C 500 mg28.3
Mebendazole Polymorph C 500 mg18.8

[back to top]

Prevalence of Ascaris Infection

Prevalence of Ascaris infection is defined by the number of participants with any Ascaris worm eggs present in their stool sample as analyzed with microscopy. (NCT01905423)
Timeframe: 2 Years

,,,,
InterventionParticipants (Count of Participants)
BaselineYear 1Year 2
Lewomada (1x Annual MDA)561718
Paga (1x Annual MDA)88135107
Pekalongan (1x Annual MDA)19110
Pekalongan (2x Annual MDA)5860
Pruda (2x Annual MDA)3473

[back to top]

Prevalence of Circulating Filarial Antigen in Blood as Determined by ICT Card Test

"Prevalence of filarial antigenemia (detected with the Binax Filariasis Now card test ICT card test) among the population surveyed. Prevalence data are expressed as %." (NCT01905423)
Timeframe: 3 years

,,,,
InterventionParticipants (Count of Participants)
BaselineYear 1Year 2Year 3
Lewomada (1x Annual MDA)47121336
Paga (1x Annual MDA)14020
Pekalongan (1x Annual MDA)1185100
Pekalongan (2x Annual MDA)1026300
Pruda (2x Annual MDA)2359110672

[back to top]

Prevalence of Hookworm Infection

Prevalence of hookworm infection is defined by the number of participants with any hookworm eggs present in their stool sample as analyzed with microscopy. (NCT01905423)
Timeframe: 2 years

,,,,
InterventionParticipants (Count of Participants)
BaselineYear 1Year 2
Lewomada (1x Annual MDA)22611897
Paga (1x Annual MDA)2511865
Pekalongan (1x Annual MDA)000
Pekalongan (2x Annual MDA)000
Pruda (2x Annual MDA)359087

[back to top]

Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood

Microfilariae (filarial parasites) will be detected in blood smears by microscopy. Samples will be collected in annual and semiannual community surveys. Prevalence rates (a measure of the disease rates in the population sampled) are expressed as % positive for microfilaremia (having microfilaria in the blood). (NCT01905423)
Timeframe: 3 years

,,,,
InterventionParticipants (Count of Participants)
Baseline (pre-MDA)Year 1Year 2Year 3
Lewomada (1x Annual MDA)36963
Paga (1x Annual MDA)541160
Pekalongan (1x Annual MDA)462800
Pekalongan (2x Annual MDA)453000
Pruda (2x Annual MDA)146371512

[back to top]

Prevalence of Positive Brugia Rapid Antifilarial Antibody Tests

This outcome is reported as the frequency of participants with positive Brugia Rapid antifilarial antibody tests. Data was only collected at baseline and at year 3 for this outcome measure and no antibody data was collected for the Pekalongan study sites. (NCT01905423)
Timeframe: 3 years

,,,,
InterventionParticipants (Count of Participants)
BaselineYear 1Year 2Year 3
Lewomada (1x Annual MDA)22916813436
Paga (1x Annual MDA)1750016
Pekalongan (1x Annual MDA)0000
Pekalongan (2x Annual MDA)0000
Pruda (2x Annual MDA)2970037

[back to top]

Prevalence of Trichuris Infection

Prevalence of trichuris infection is defined by the number of participants with any trichuris worm eggs present in their stool sample as analyzed with microscopy. (NCT01905423)
Timeframe: 2 years

,,,,
InterventionParticipants (Count of Participants)
BaselineYear 1Year 2
Lewomada (1x Annual MDA)452523
Paga (1x Annual MDA)689384
Pekalongan (1x Annual MDA)120350
Pekalongan (2x Annual MDA)352650
Pruda (2x Annual MDA)8813

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Mebendazole

The Time to Reach Maximum Plasma Concentration (Tmax) is time to reach the maximum plasma concentration. (NCT02034162)
Timeframe: Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)

Interventionhours (Mean)
Mebendazole: Group 1 (1 to <3 Years)2.5
Mebendazole: Group 2 (3 to 6 Years)2
Mebendazole: Group 3 (7 to 16 Years)3

[back to top]

Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours (AUC8h) of Mebendazole

The (AUC8h) is the area under the plasma concentration-time curve from time 0 to 8 hours Post-dose. (NCT02034162)
Timeframe: Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)

Interventionnanogram hour per Milliliters(ng*h/mL) (Mean)
Mebendazole: Group 1 (1 to <3 Years)697
Mebendazole: Group 2 (3 to 6 Years)242
Mebendazole: Group 3 (7 to 16 Years)182

[back to top]

Area Under the Plasma Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-last) of Mebendazole

The (AUC [0-last]) is the area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration. (NCT02034162)
Timeframe: Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)

Interventionng*h/mL (Mean)
Mebendazole: Group 1 (1 to <3 Years)1320
Mebendazole: Group 2 (3 to 6 Years)416
Mebendazole: Group 3 (7 to 16 Years)387

[back to top]

Cure Rate for Ascaris Lumbricoides at the End of Double-blind Treatment Period

Cure is defined as a post-treatment egg count of zero in participants who had a positive egg count at baseline. (NCT02034162)
Timeframe: At Visit 3 (Day 19) of Double-blind treatment period

Interventionpercentage of participants (Number)
Double-blind Placebo11.1
Double-blind Mebendazole 500 mg83.7

[back to top]

Cure Rate for Trichuris Trichiura at the End of Double-blind Treatment Period

Cure is defined as a post-treatment egg count of zero in participants who had a positive egg count at baseline. (NCT02034162)
Timeframe: At Visit 3 (Day 19) of Double-blind treatment period

Interventionpercentage of participants (Number)
Double-blind Placebo7.6
Double-blind Mebendazole 500 mg33.9

[back to top]

Egg Count Reduction Rate (Percent) for Ascaris Lumbricoides Infestation at the End of Double-blind Treatment Period

Percent egg count reduction is calculated as average egg count at end of treatment period of a treatment group minus average egg count at baseline of the treatment group divided by average egg count at baseline of the treatment group. (NCT02034162)
Timeframe: Baseline and Day 19 (Visit 3) at the End of Double-blind Treatment Period

Interventionpercent change in egg count (Number)
Double-blind Placebo-19.2
Double-blind Mebendazole 500 mg-97.9

[back to top]

Egg Count Reduction Rate (Percent) for Trichuris Trichiura Infestation at the End of Double-blind Treatment Period

Percent egg count reduction is calculated as average egg count at end of treatment period of a treatment group minus average egg count at baseline of the treatment group divided by average egg count at baseline of the treatment group. (NCT02034162)
Timeframe: Baseline and Day 19 (Visit 3) at the End of Double-blind Treatment Period

Interventionpercent change in egg count (Number)
Double-blind Placebo-10.5
Double-blind Mebendazole 500 mg-59.7

[back to top]

Maximum Plasma Concentration (Cmax) of Mebendazole

The Cmax is the maximum plasma concentration. (NCT02034162)
Timeframe: Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)

Interventionnanogram per Milliliters (ng/mL) (Mean)
Mebendazole: Group 1 (1 to <3 Years)210.0
Mebendazole: Group 2 (3 to 6 Years)49.9
Mebendazole: Group 3 (7 to 16 Years)34.2

[back to top]

Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Double-Blind Treatment Period

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT02034162)
Timeframe: Up to Visit 3 (Day 19 +/-2)

Interventionparticipants (Number)
Double-blind Placebo8
Double-blind Mebendazole 500 mg9

[back to top]

Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Open-Label Treatment Period

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT02034162)
Timeframe: At Visit 3 (Day 19+/-2) followed up to Visit 5 (Day 7+/-1 from Visit 3)

Interventionparticipants (Number)
Open-label Mebendazole 500 mg7

[back to top]

Arithmetic ERR of Both Mebendazole Regimens Against Trichuris Trichiura

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(arithmetic mean EPG at follow-up/arithmetic mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (arithmetic mean at follow-up/arithmetic mean at baseline)*100)." (NCT03245398)
Timeframe: baseline (before treatment) and 18 to 22 days post-treatment

Interventionpercentage change (Mean)
Single 500 mg Dose of Mebendazole-49.1
Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole-91.6

[back to top]

Arithmetic ERR of the Two Regimens of Mebendazole Against Hookworm

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(arithmetic mean EPG at follow-up/arithmetic mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (arithmetic mean at follow-up/arithmetic mean at baseline)*100)." (NCT03245398)
Timeframe: baseline (before treatment) and 18 to 22 days post-treatment

Interventionpercentage change (Mean)
Single Dose of Mebendazole-52.7
Multiple Dose of Mebendazole-99.8

[back to top]

CR of Both Mebendazole Regimens Against Trichuris Trichiura

Cure rates (CRs) will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment. (NCT03245398)
Timeframe: baseline (before treatment) and 18 to 22 days post-treatment

Interventionpercentage of participants cured (Number)
Single 500 mg Dose of Mebendazole6.8
Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole42.9

[back to top]

Cure Rate (CR) of Both Mebendazole Regimens Against Ascaris Lumbricoides

Cure rates (CRs) will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment. (NCT03245398)
Timeframe: baseline (before treatment) and 18 to 22 days post-treatment

Interventionpercentage of participants cured (Number)
Single 500 mg Dose of Mebendazole100
Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole98

[back to top]

Cure Rate (CR) of Mebendazole Against Hookworm

Cure rates (CRs) will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment. (NCT03245398)
Timeframe: baseline (before treatment) and 18 to 22 days post-treatment

Interventionpercentage of participants cured (Number)
Single 500 mg Dose of Mebendazole13
Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole97.9

[back to top]

Geometric ERR of Both Mebendazole Regimens Against Ascaris Lumbricoides.

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100)." (NCT03245398)
Timeframe: baseline (before treatment) and 18 to 22 days post-treatment

Interventionpercentage change (Mean)
Single 500 mg Dose of Mebendazole-100
Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole-100

[back to top]

Geometric ERR of Both Mebendazole Regimens Against Trichuris Trichiura

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100)." (NCT03245398)
Timeframe: baseline (before treatment) and 18 to 22 days post-treatment

Interventionpercentage of change (Mean)
Single 500 mg Dose of Mebendazole-71.7
Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole-98.1

[back to top]

Geometric Mean Egg Reduction Rate (ERR) of the Two Regimens of Mebendazole Against Hookworm

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100)." (NCT03245398)
Timeframe: baseline (before treatment) and 18 to 22 days post-treatment

Interventionpercentage change (Geometric Mean)
Single 500 mg Dose of Mebendazole-68.0
Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole-100

[back to top]

Arithmetic ERR of Both Mebendazole Regimens Against Ascaris Lumbricoides

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(arithmetic mean EPG at follow-up/arithmetic mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (arithmetic mean at follow-up/arithmetic mean at baseline)*100)." (NCT03245398)
Timeframe: baseline (before treatment) and 18 to 22 days post-treatment

Interventionpercentage change (Mean)
Single 500 mg Dose of Mebendazole-100
Multiple (Bid for 3 Days) Dose of 100 mg Mebendazole-99.1

[back to top]

Arithmetic ERR of the Two Formulations of Mebendazole Against Hookworm

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(arithmetic mean EPG at follow-up/arithmetic mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (arithmetic mean at follow-up/arithmetic mean at baseline)*100)." (NCT03995680)
Timeframe: Baseline (before treatment) and sometime between 14 and 21 days post-treatment

Interventionpercentage change in hookworm egg counts (Number)
Chewable Tablet of Mebendazole38.2
Swallowable Tablet of Mebendazole28.1

[back to top]

CR of Both Mebendazole Formulations Against Ascaris Lumbricoides

Cure rates (CRs) will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment. (NCT03995680)
Timeframe: Baseline (before treatment) and sometime between 14 and 21 days post-treatment

Interventionpercentage of participants (Number)
Chewable Tablet of Mebendazole95.3
Swallowable Tablet of Mebendazole97.8

[back to top]

CR of Both Mebendazole Regimens Against Trichuris Trichiura

Cure rates (CRs) will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment. (NCT03995680)
Timeframe: Baseline (before treatment) and sometime between 14 and 21 days post-treatment

Interventionpercentage of participants (Number)
Chewable Tablet of Mebendazole9.8
Swallowable Tablet of Mebendazole7.3

[back to top]

Cure Rate (CR) of Mebendazole Against Hookworm

Cure rates (CRs) will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment. (NCT03995680)
Timeframe: Baseline (before treatment) and sometime between 14 and 21 days post-treatment

Interventionpercentage of participants (Number)
Chewable Tablet of Mebendazole12.7
Swallowable Tablet of Mebendazole11.2

[back to top]

Geometric ERR of Both Mebendazole Formulations Against Ascaris Lumbricoides.

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100)." (NCT03995680)
Timeframe: Baseline (before treatment) and sometime between 14 and 21 days post-treatment

Interventionpercentage change in A. lumbr egg counts (Number)
Chewable Tablet of Mebendazole99.9
Swallowable Tablet of Mebendazole99.9

[back to top]

Geometric ERR of Both Mebendazole Formulations Against Trichuris Trichiura

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100)." (NCT03995680)
Timeframe: Baseline (before treatment) and sometime between 14 and 21 days post-treatment

Interventionpercentage change in T. trich egg counts (Number)
Chewable Tablet of Mebendazole73.3
Swallowable Tablet of Mebendazole74.2

[back to top]

Geometric Mean Egg Reduction Rate (ERR) of the Two Formulations of Mebendazole Against Hookworm

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100)." (NCT03995680)
Timeframe: Baseline (before treatment) and sometime between 14 and 21 days post-treatment

Interventionpercentage change in hookworm egg counts (Number)
Chewable Tablet of Mebendazole68.5
Swallowable Tablet of Mebendazole70.8

[back to top]

Arithmetic ERR of Both Mebendazole Formulations Against Trichuris Trichiura

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(arithmetic mean EPG at follow-up/arithmetic mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (arithmetic mean at follow-up/arithmetic mean at baseline)*100)." (NCT03995680)
Timeframe: Baseline (before treatment) and sometime between 14 and 21 days post-treatment

Interventionpercentage change in T. trich egg counts (Number)
Chewable Tablet of Mebendazole52.9
Swallowable Tablet of Mebendazole50.9

[back to top]

Arithmetic ERR of Both Mebendazole Formulations Against Ascaris Lumbricoides

"Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(arithmetic mean EPG at follow-up/arithmetic mean EPG at baseline))*100). Note: in contrast to the publication the outcome measure entry mask requires the complementary percentage: (arithmetic mean at follow-up/arithmetic mean at baseline)*100)." (NCT03995680)
Timeframe: Baseline (before treatment) and sometime between 14 and 21 days post-treatment

Interventionpercentage change in A. lumbr egg counts (Number)
Chewable Tablet of Mebendazole98.7
Swallowable Tablet of Mebendazole99.8

[back to top]